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ABSTRACT 
 
Carri Brodnax Geer:  Analytical Studies on the Mechanism of Fibrin Formation 
(Under the direction of Dr. Susan Lord and Dr. Mark Schoenfisch) 
 
    
    Fibrinogen plays a crucial role in hemostasis, the regulation and maintenance of blood 
flow, and mediates surface-induced thrombosis at blood-contacting materials (e.g., 
implantable medical devices).  Fibrinogen binds platelets and polymerizes to form fibrin, the 
structural scaffold of blood clots.  The mechanisms by which fibrin formation is influenced 
by the surface properties of a material or therapeutic agents used to prevent platelet 
aggregation (e.g., S-nitrosothiols) are unclear.  In addition, the exact mechanism of fibrin 
formation in solution remains controversial.  Herein, the mechanism of fibrin formation in 
solution and at surfaces was investigated using surface-based analytical methods (surface 
plasmon resonance and atomic force microscopy).  Additionally, the influence of S-
nitrosoglutathione (a potent anti-platelet therapeutic) and its decomposition products on the 
mechanism of fibrin formation were examined by turbidity measurements.   
    The affinities of two fibrin fragments (desA-NDSK and desAB-NDSK) binding to 
fibrinogen were compared by SPR.  The affinities of desA- and desAB-NDSK (5.8 ± 1.1 and 
3.7 ± 0.7 µM, respectively) were not statistically different from one another.  Peptide 
inhibition studies showed “B-b” interactions occurred between desAB-NDSK but not desA-
NDSK and fibrinogen, indicating “B-b” interactions may occur simultaneously to “A-a” 
interactions and between the same to interacting molecules.  An atomic force microscopy 
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method was developed to study the ruptures that occur upon the forced dissociation of desA-
NDSK and desAB-NDSK from fibrinogen.  The protein immobilization strategy and data 
collection procedures were varied to minimize multiple interactions and non-specific forces.  
Unlike the SPR experiments, “B-b” interactions were not detected in the forced dissociation 
of desAB-NDSK from fibrinogen. 
    The influence of S-nitrosoglutathione on the mechanism of fibrin formation was studied 
using turbidity measurements.  S-nitrosogluathione (GSNO) and its decomposition products 
(reduced and oxidized glutathione, GSH and GSSG, respectively) each inhibited fibrin 
formation as evidenced by longer lag times, lower Vmax values and lower final optical 
densities.  GSH, GSSG and GSNO have numerous roles in physiology.  However, the work 
presented herein is the first report of the inhibition of fibrin formation by GSH and GSSG.           
    Lastly, the role of surface properties on the mechanism of fibrin formation at surfaces was 
studied by SPR.  Fibrinogen was adsorbed to a hydrophobic and negatively charged surface 
and the availability of fibrinopeptide A (FpA), a critical site for thrombin activation, were 
measured by antibody binding.  Approximately 3 times more FpA was measured on 
fibrinogen adsorbed at the hydrophobic surface compared to the negatively charged surface, 
indicating surface properties strongly influence the availability of FpA on adsorbed 
fibrinogen.  By better understanding the mechanism of fibrin formation in solution and at 
surfaces, researchers may be able design materials or therapies to improve the standard of 
care in hemostatic disorders and improve the blood-compatibility of currently available 
medical devices.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 Physiological Significance of Fibrinogen 
    Synthesized predominantly in the liver, fibrinogen is a plasma protein present in blood at a 
concentration of approximately 2.5 mg/mL (1).  Fibrinogen’s primary role is in hemostasis, 
the regulation and maintenance of blood flow.  During a vascular injury or bleeding event, 
fibrinogen bridges activated platelets to help form the initial platelet plug to stem the flow of 
blood (2, 3).  Subsequently, the enzyme thrombin converts fibrinogen to fibrin polymer, the 
structural scaffolding of the blood clot that stabilizes the initial platelet plug to prevent 
further bleeding.  Fibrin also localizes cells and proteins critical to wound healing and 
inflammation to the site of injury to promote vessel repair and regrowth.  For example, 
fibrinogen and fibrin contain binding sites for fibroblast growth factor-2 and vascular 
endothelial growth factor, two proteins critical to wound healing and angiogenesis, 
respectively (4, 5). In addition to hemostasis, wound healing, and inflammation, fibrinogen 
has been shown to be an important indicator of cardiovascular health.  Elevated fibrinogen 
levels in the blood may serve as a predicative marker for cardiovascular disease and/or stroke 
(6, 7).    
    Fibrinogen is also of great interest to the biomaterials community.  Plasma protein 
adsorption is the first event to occur when blood contacts a surface.  Research has shown the 
nature of the adsorbed protein layer dictates the body’s subsequent response to the foreign 
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material (8-11).  For example, albumin and immunoglobulin G (IgG) are present at much 
higher concentrations in plasma than fibrinogen, and thus among the first proteins to interact 
with the surface of a blood-contacting material.  Because fibrinogen has a much higher 
affinity for surfaces, it quickly displaces albumin and IgG through a competitive adsorption 
process known as the Vroman effect (12, 13).  Over the time scale of seconds to minutes, 
fibrinogen becomes the predominant protein at the surface.  Eventually fibrinogen is 
displaced by high molecular weight kininogen at extended periods (e.g., minutes to hours) 
(13, 14).  Regardless, fibrinogen is present at the surface at high concentrations during the 
time of surface-induced thrombosis and the initial stages of wound healing and inflammation.  
Each of these three processes have been shown to ultimately determine the biocompatibility 
of a blood-contacting material (8-10).  Due to its importance in multiple critical biological 
functions, a deeper understanding of fibrinogen-surface interactions and fibrinogen’s 
function at surfaces may lead to the design of more biocompatible materials. 
 
1.2 Fibrinogen Structure 
    As with most large proteins, fibrinogen’s structure and function are complex.  A detailed 
schematic of fibrinogen’s structure is shown in Figure 1.1.  This 340 kDa hexameric 
glycoprotein is composed of two copies each of three polypeptide chains: Aα (610 amino 
acids), Bβ (461 amino acids) and γ (411 amino acids) and contains 29 disulfide bonds (15-
19).  The N-termini of all 6 chains are held together by 11 disulfide bonds in the center of the 
molecule, the E region.  All three chains extend outward from the E region via a coiled-coil 
segment that terminates in a second, structurally important region of the molecule, the D 
region.  The two distally located D regions are comprised of the C-termini of the Bβ and γ  
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Figure 1.1  Schematic of fibrinogen.   
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chains that fold into two smaller structures, the βC and γC modules, respectively.  The γC 
and βC module each contain a binding pocket critical to polymerization, hole “a” and “b”, 
respectively.  The C-termini of the α chains extend outward from the coiled-coils and 
terminate in small, globular structures, the αC regions.  The two αC regions interact with 
each other and the N-termini of the Aα and Bβ chains in the E region (20).  In addition to its 
role in fibrin formation and platelet aggregation, fibrinogen interacts with a host of other 
proteins and cells.  For example, both fibrinogen and fibrin recruit neutrophils, monocytes 
and fibroblasts to the site of injury, localizing important cells to promote inflammation and 
wound healing (21).  Fibrin(ogen)’s presence at the site of injury has also been exploited by 
Staphylococcus aureus, a deadly bacterial pathogen.  S. aureus expresses fibrin(ogen)-
specific receptors on its cell surface that help to localize the bacteria at the site of injury and 
facilitate infection (22, 23).  Other proteins, such as albumin, von Willebrand factor and 
fibronectin have been shown to interact with fibrin(ogen), illustrating the wide-range of 
species that can interact with a single plasma protein (15).   
            
1.3 Formation of Fibrin 
    1.3.1 The coagulation cascade.  Fibrin formation in vivo is the result of a complex series 
of interactions collectively known as the coagulation cascade that are localized at specific 
cell surfaces (Fig. 1.2) (2, 3).  Vascular injury interrupts the endothelium, the layer of cells 
lining blood vessel walls, to expose tissue factor-bearing cells such as fibroblasts to blood.  
The initial phase of coagulation occurs on the surface of the tissue factor-bearing cells.  
Circulating inactivated coagulation factor VII becomes activated and associates with 
membrane-bound tissue factor.  The VIIa/tissue factor complex converts factor IX and X to  
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Figure 1.2  Schematic of the cell-based model of hemostasis adapted from (3). 
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IXa and Xa, respectively.  Factor Xa in turn associates with Va on the cell surface.  The 
Xa/Va complex converts a small amount of factor II (prothrombin) to IIa (active thrombin).  
The generation of the small, initial amount of thrombin at the surface of the tissue factor-
bearing cells is responsible for the activation of additional coagulation factors such as XI, V 
and the VIII/von Willebrand factor complex.  More importantly, initial thrombin generation 
serves to activate circulating platelets.  The activated platelets aggregate to form a platelet 
plug that slows/stops the flow of blood at the wound.  Once activated platelets are localized 
at the site of injury, large-scale thrombin generation occurs at the platelet surface.  Factor IXa 
associates with VIIIa on the surface of the activated platelet to generate additional Xa.  The 
same Xa/Va complex that forms on the surface of the tissue factor-bearing cell also forms on 
the surface of the platelet (Fig. 1.2).  The coagulation cascade culminates in the generation of 
large amounts of thrombin on the surface of activated platelets.  The large-scale thrombin 
generation is responsible for the conversion of soluble circulating fibrinogen into insoluble 
fibrin polymer shown in Figure 1.3.     
 
    1.3.2 Thrombin-catalyzed conversion of fibrinogen to fibrin.  Thrombin is a 39 kDa serine 
protease that cleaves a peptide bond between arginine and glycine within fibrinogen (24, 25).  
Thrombin has a positively charged region on its surface that binds specific negatively 
charged regions of fibrinogen.  The thrombin binding sites on fibrinogen are remote to the 
cleavage sites (26-28).  Thrombin binding to fibrinogen properly aligns the polypeptide 
chain, allowing for efficient enzymatic cleavage.  In the generally accepted mechanism of  
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Figure 1.3  Scanning electron micrograph of insoluble fibrin polymer illustrating the mesh-
like structure of the fibrin network.     
 
 
 
 
 
 
 
 
 
 
 
2 µm
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fibrin formation (Fig. 1.4), thrombin first cleaves fibrinopeptide A (FpA), the first 16 amino 
acids of fibrinogen’s Aα chain (29).  Removal of FpA exposes Gly-Pro-Arg, the “A” knob, 
as the new N-terminal sequence of α chain (30).  After FpA removal, the activated fibrinogen 
is referred to as desAA-fibrin monomer.  The desAA-fibrin monomers spontaneously align to 
form half-staggered, double-stranded protofibrils held together by “A-a” knob-hole 
interactions between the “A” knobs and holes “a” located in the D regions of fibrinogen (Fig. 
1.4) (31).  Next, thrombin cleaves fibrinopeptide B (FpB), the first 14 amino acids of the Bβ 
chain.  Removal of FpB occurs from the desAA-fibrin monomers within the protofibril 
structures, to expose Gly-His-Arg-Pro, termed the “B” knob, as the new sequence of the β 
chain.  Analogous to “A-a” interactions, “B-b” interactions occur when the “B” knobs 
interact with holes “b” (Fig. 1.4).  After FpB removal the protofibrils laterally aggregate and 
branch to form a dense fibrin network (30, 32).   
    While the importance of “A-a” interactions is well-understood, the role of “B-b” knob-
hole interactions is surrounded by controversy.  Many researchers believe “B-b” interactions 
are responsible for the lateral aggregation of protofibrils to form fibers.  Studies have 
demonstrated that lateral aggregation is enhanced by FpB release, suggesting “B-b” 
interactions contribute to the lateral aggregation of protofibrils (33).  Alternatively, clots can 
be formed in the absence of “B-b” interactions altogether.  For example, certain snake venom 
enzymes cleave only FpA, and thereby no “B-b” interactions are possible(30).  To further 
obscure the role of “B-b” interactions in fibrin formation, studies have shown clots can form 
when “B-b” interactions are the principle knob-hole interaction (34, 35).  However, clots 
formed from “B-b” interactions were only observed at temperatures below physiological 
conditions (e.g., 15 ºC) and “A-a” interactions were not excluded entirely (36-41).   
 9
      
 
Figure 1.4  Proposed mechanism of thrombin-catalyzed fibrin formation. 
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    1.3.3 Factors that influence fibrin formation.  As discussed in Section 1.1, many proteins 
and cells interact with fibrinogen and fibrin during thrombosis, inflammation and wound-
healing.  Other parameters such as pH, chloride and calcium ion concentration, reducing 
agents and temperature may also affect the conversion of fibrinogen to fibrin (15, 18, 42).    
For example, calcium stabilizes fibrinogen’s structure, accelerates fibrin formation and can 
partially protect fibrinogen from reduction and/or degradation (42-45).  Some agents interact 
with fibrinogen directly to alter its function (e.g., pH, calcium and reducing agents), while 
others may interfere with fibrinogen and platelet activation to influence fibrin formation (25, 
41, 46).  For example, aspirin has been shown to inhibit platelet aggregation and acetylate 
lysine residues in fibrinogen leading to an altered, more permeable clot structure (46).   
    Endogenous and exogenous S-nitrosothiols (e.g., S-nitrosogluathione and S-
nitrosopenacillamine) have emerged as a class of compounds with potent antiplatelet 
properties (47-49).  S-nitrosothiols or RSNOs are considered nitric oxide (NO) donors 
because they readily transfer NO directly via transnitrosation reactions or decomposition to 
evolve NO, producing the thiol, thiyl radical or the disulfide (47-49).  The reactive by-
products of NO may interact with proteins via nitrosation of tyrosine or cyseine residues, 
leading to potential structural and/or functional alterations.  S-nitrosoglutathione, an 
endogenous S-nitrosothiol, inhibits platelet aggregation and activation via two mechanisms, 
the transnitrosation of thiol residues in critical membrane proteins and the disruption of 
intracellular signaling via direct release of nitric oxide (36-41).  Despite the abundance of 
research investigating the effects of S-nitrosothiols on platelets and numerous proteins, only 
one study to date has examined the effect of the S-nitrosothiols on fibrin formation, the 
physiological product of platelet aggregation/activation.  Mutus and coworkers found both 
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endogenous and exogenous S-nitrosothiols, S-nitrosoglutathione and S-nitrosopenacillamine, 
respectively inhibit the initial rate of fibrin formation (50).  Of note, reports on the effects of 
S-nitrosothiols and their decomposition products (e.g., S-nitrosoglutathione, oxidized and 
reduced glutathione) on the entire process of fibrin formation do not exist.  In addition to its 
relevance as a decomposition product of S-nitrosoglutathione, glutathione is present in 
plasma at ~500 µM and may play a role in platelet function and/or fibrin formation (51).  
Glutathione and its disulfide are primarily responsible for maintaining the oxidative balance 
inside cells and blood (52).   For example, glutathione levels change in patients with 
oxidative stress induced by cancer or smoking (53, 54).  Given the dual importance of 
glutathione as a decomposition product of S-nitrosogluathione therapies for thrombosis and 
its presence in plasma as a reducing agent, understanding the effects of glutathione on fibrin 
formation may provide new and crucial insight into the role nitrosothiols and thiols in 
physiology.   
 
1.4 Fibrin Formation at Surfaces 
    1.4.1 Surface-Induced Thrombosis.  A consequence of poor biocompatibility is surface 
induced thrombosis, or the undesirable formation of a fibrin clot at the blood/material 
interface.  Clots formed at the blood/material interface may occlude blood flow to/past the 
medical device, impair proper function of the device, and/or dislodge from the surface and 
cause thrombotic embolism.  The initial event in the surface-induced thrombosis is plasma 
protein adsorption, a process that mediates subsequent cellular interactions between platelets, 
immune and inflammatory cells and the adsorbed proteins at the surface of the material (11).  
Of all plasma proteins, fibrinogen is of particular importance in surface-induced thrombosis 
 12
because of its dual role in modulating platelet adhesion and fibrin polymer formation.  Much 
research has been devoted to understanding fibrinogen’s role in surface-induced thrombosis 
and the influence of surface properties (9, 10, 55).  For example, Tang and co-workers 
examined biomaterial-associated inflammation and found fibrinogen adsorption was required 
for phagocyte-material interactions that mediated subsequent inflammation (8, 56).  
   
    1.4.2 Fibrinogen Adsorption to Surfaces.  Specific adsorption characteristics of fibrinogen 
including surface coverage, orientation and conformation have been widely studied at 
numerous surfaces and are well-documented in the literature (13, 57-64).  Previous work 
from the Schoenfisch laboratory has demonstrated equivalent amounts of fibrinogen 
adsorbed to model hydrophobic, positively and negatively charged self-assembled 
monolayers (SAMs), yet a reduced amount of fibrinogen adsorbed to the hydrophilic surface 
(65).   Other research has focused on understanding how surface properties influence the 
function of adsorbed fibrinogen as it relates to platelet adhesion (14, 66-72).  Fibrinogen in 
solution does not interact with platelets, yet fibrinogen adsorbed at a surface undergoes 
conformational changes to expose the platelet binding site (66, 73, 74).  Platelets readily bind 
to adsorbed fibrinogen, leading to their activation and the initiation of the coagulation 
cascade.  Platelet adhesion to surfaces via interactions with adsorbed fibrinogen is of 
particular interest to biomaterial investigators because preventing the initiation of the 
coagulation cascade and subsequent thrombus formation may lead to more thromboresistant 
materials (55, 67, 68, 71, 72).  To date, no known surface has demonstrated complete 
resistance to protein adsorption and even as little as 1% of a fibrinogen monolayer is 
sufficient to lead to significant platelet interactions with the surface (75).   
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    1.4.3. Fibrin Formation at Surfaces. While a wealth of information exists regarding 
fibrinogen adsorption to a variety of materials and subsequent platelet interactions with 
immobilized fibrinogen, comparatively little research has focused on the influence of surface 
properties on fibrinogen’s primary function: fibrin formation.  Sit and Marchant visualized 
differences in fibrin assembly on hydrophobic graphite versus negatively charged mica 
surfaces using atomic force microscopy (76).  Fibrinogen was adsorbed to the substrate, 
treated with thrombin and imaged as activated fibrin monomers were titrated into the AFM 
fluid cell.  At the hydrophobic surface short fibrin strands formed first, followed by the 
formation of longer, branched fibrin strands.  The final result was the formation of a full 
fibrin network.  However, at the negatively charged surface the fibrin monomers aggregated 
and fibrin network formation was not observed.  The authors hypothesized that fibrin 
formation at the negatively charged substrate was impaired due to several possibilities.  First, 
the electrostatic interactions of fibrin assembly were abrogated due to the overwhelming 
interference of the electrostatic interactions between the proteins and the negatively charged 
mica.  For example, fibrinogen has a net negative charge due in part to the highly negatively 
charged fibrinopeptides.  Upon thrombin’s removal of the fibrinopeptides, the E region of 
fibrinogen becomes positively charged.  Interactions between the positively charged E region 
and the mica could render the positively charged polymerization “knobs” unavailable to 
interact with the negatively charged “holes” located in D regions of fibrin(ogen) molecules.  
Another explanation offered for the impaired fibrin formation at negatively charged 
substrates was potential interference with thrombin’s activity.  Thrombin binds to a 
negatively charged region in fibrinogen via a positively charged site on its exterior (26).  
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Interactions between the positively charged region on thrombin and the negatively-charged 
mica could prevent thrombin from cleaving fibrinopeptides from fibrinogen and thereby 
prevent fibrin formation.           
While the studies by Sit and Marchant represent the first examination of the surface-
dependence of fibrin formation, subsequent work in the Schoenfisch laboratory expanded the 
investigation to include not only hydrophobic and negatively charged surfaces, but 
hydrophilic and positively charged surfaces as well.  Using quartz crystal microbalance 
(QCM) and scanning electron microscopy, Evans-Nguyen and Schoenfisch found that 
surface properties influence the amount and morphology of the fibrin clots (65).  The 
surfaces of the quartz mass sensors were modified with alkanethiol self-assembled 
monolayers terminating in methyl (hydrophobic), hydroxyl (hydrophilic), amine (positively 
charged) or carboxylate (negatively charged) groups.  The crystals were exposed to 
fibrinogen to initiate adsorption and the mass of adsorbed fibrinogen measured for each 
surface.  Next, thrombin was added to the fibrinogen solution to initiate clot formation and 
the mass of fibrin at each surface was monitored in real time.   
Of note, equivalent amounts of fibrinogen adsorbed to the hydrophobic, positively and 
negatively charged QCM crystals, yet significantly different fibrin structures were formed at 
each surface after thrombin addition.  Similar to the findings reported by Sit and Marchant 
(76), Evans-Nguyen and Schoenfisch observed a stark contrast in the morphology and 
amount of fibrin formed at the hydrophobic versus negatively charged surface (65).  Fibrin 
fibers appeared dense and branched on the hydrophobic surface, and closely resembled fibrin 
formed in solution.  Fibrin fibers formed at the negatively charged surface were sparse and 
thin with noticeably fewer branch points.  The amount of fibrin formed at the positively 
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charged surface was intermediary to the fibrin at the hydrophobic and negatively charged 
surfaces.     
Collectively, the studies by Sit and Marchant and Evans-Nguyen and Schoenfisch clearly 
demonstrate fibrin formation at surfaces is influenced by the underlying substrate.  More 
specifically, charge and wettability significantly influence the amount and architecture of 
fibrin fibers formed at surfaces.        
 
1.4.4 Thrombin Interactions with Adsorbed Fibrinogen.  To better understand how surface 
properties may influence fibrin formation, Evans-Nguyen et al. examined the initial phase of 
fibrin formation (i.e., the interaction between thrombin and fibrinogen) (65).  Fibrinogen 
adsorbed to model hydrophobic, hydrophilic, positively and negatively charged substrates 
was treated with thrombin and the amount of FpA and FpB released from the adsorbed 
fibrinogen was monitored using HPLC-MS.  The amount and rate of FpA and FpB release 
correlated well with the extent of fibrin formation observed in earlier studies.  The fibrinogen 
adsorbed at the hydrophobic and positively charged surfaces exhibited the greatest amount 
and rate of fibrinopeptide release, suggesting thrombin was able to interact effectively with 
the adsorbed fibrinogen.  The hydrophilic surface showed slightly less effective 
fibrinopeptide release compared to the hydrophobic and positively charged surfaces.  Not 
surprising, the amount and rate of fibrinopeptide release was significantly reduced for 
fibrinogen adsorbed at the negatively charged surface, indicating severe impediments to the 
interaction between thrombin and fibrinogen.  In addition to electrostatic interferences 
between the positively charged regions on thrombin responsible for fibrinogen recognition, 
the authors hypothesized that conformational changes resulting from adsorption could 
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explain the surface-dependent fibrinopeptide release properties.  For example, Sit and 
Marchant used AFM to observe that fibrinogen adsorbed on hydrophobic and positively 
charged substrates underwent significantly more spreading compared to fibrinogen adsorbed 
at a negatively charged substrate (77).  Therefore, the observed surface-dependent 
interactions between thrombin and adsorbed fibrinogen may be the result of surface-
dependent conformational changes in addition to electrostatic interferences.  
 
    1.4.5 Study of Forces Involved in Fibrin Formation.  As described above, several surface-
based analytical methods have proven useful for studying various phases of fibrin formation.  
In addition to imaging adsorbed fibrinogen and fibrin structures, the atomic force microscope 
(AFM) has been used to probe the mechanical properties of fibrin fibers and fibrinogen 
oligomers.  Guthold and co-workers used the AFM tip to stretch individual fibrin fibers and 
found that they could be extended up to 330% of their original length, making fibrin the most 
extensible known biopolymer (78).  Weisel and co-workers used AFM to study the stretching 
of fibrinogen oligomers between the AFM tip and substrate (79).  The authors observed a 
characteristic force pattern corresponding to the unfolding of individual domains within the 
fibrinogen polymers and they hypothesized the forces were related to the unfolding of the 
coiled-coil region in fibrinogen (80).   
    In other work, Weisel and co-workers examined the individual forces between fibrin(ogen) 
and its fragments using laser tweezers.  The rupture force of “A-a” and “B-b” knob-hole 
interactions were measured in addition to αC-αC and αC-N-terminus of the Bβ chains.  By 
understanding the individual bonds responsible for holding two fibrin molecules together and 
the magnitudes of those interactions, a better understanding of the physical properties of 
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fibrin may be possible.  However, laser tweezers technology has several limitations.  For 
example, the optical trap controlling the modified beads has a maximum strength of 200 pN, 
limiting the range of detectable interactions.  Also, the spatial resolution is only accurate to 
within several nanometers (80-84).  Consequently, mechanical behaviors of molecules (e.g., 
unfolding or stretching) occurring on the Å to nm scale immediately preceding bond rupture 
are not resolved from the bond rupture itself using laser tweezers.  In this regard, the AFM 
has superior capabilities compared to laser tweezers.  The AFM can measure both the 
magnitude and distance of bonds being ruptured, allowing researchers to study molecular 
deformations occurring within individual molecules (80, 82-84).               
  
1.5 Significance and Goals of this Work     
    To date, studies have shown how small molecules, surfaces and other proteins interact 
with fibrinogen and ultimately influence fibrin formation.  However, the mechanisms by 
which fibrin formation is influenced by certain parameters are unclear.  In addition, the exact 
mechanism of fibrin formation in solution remains controversial.  Due to the complications 
associated with the phase change of soluble fibrinogen to insoluble fibrin, the literature is 
void on the intermediate interactions of fibrin formation under physiological conditions, such 
as those between fibrin monomers and fibrinogen.  By further elucidating the mechanism of 
fibrin formation in solution and understanding how different materials influence fibrin 
formation, researchers may be able design materials or therapies to improve the standard of 
care in hemostatic disorders as well as improve currently available biomaterials.  The goals 
of my dissertation research were thus three-fold: 1) utilize surface-based analytical methods 
to further the current understanding of the mechanism of fibrin formation in solution by 
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clarifying the role of “B-b” knob-hole interactions; 2) characterize the influence of S-
nitrosoglutathione, reduced glutathione, and oxidized glutathione on the mechanism of fibrin 
formation; and, 3) investigate the mechanism by which surface properties influence fibrin 
formation.   
    The goal of Chapter 1 was to provide a brief overview of the biological significance of 
fibrinogen and its role in surface-induced thrombosis.  Chapter 2 focused on using surface 
plasmon resonance to measure the affinity of knob-hole interactions and determine whether 
“B-b” interactions occur alongside “A-a” interactions during protofibril formation and has 
been published previously (85).  Chapter 3 describes the development of an atomic force 
microscopy method to investigate the physical/mechanical properties of knob-hole 
interactions.  In Chapter 4, the effects of S-nitrosoglutathione and its decomposition products 
on the mechanism of fibrin formation were explored.  Finally, Chapter 5 examines the 
influence of surface properties on fibrinopeptide A accessibility and has been published 
previously (86).          
 
 
 19
REFERENCES 
 
(1) Redman, C. M.; Xia, H. "Fibrinogen biosynthesis. Assembly, intracellular 
degradation, and association with lipid synthesis and secretion." Ann N Y Acad Sci 
2001, 936, 480-495. 
 
(2) Hoffman, M. "A cell-based model of coagulation and the role of factor VIIa." Blood 
Rev 2003, 17 Suppl 1, S1-5. 
 
(3) Wolberg, A. S. "Thrombin generation and fibrin clot structure." Blood Rev 2007, 21, 
131-142. 
 
(4) Sahni, A.; Francis, C. W. "Vascular endothelial growth factor binds to fibrinogen and 
fibrin and stimulates endothelial cell proliferation." Blood 2000, 96, 3772-3778. 
 
(5) Sahni, A.; Odrljin, T.; Francis, C. W. "Binding of basic fibroblast growth factor to 
fibrinogen and fibrin." J Biol Chem 1998, 273, 7554-7559. 
 
(6) Meade, T. W.; Mellows, S.; Brozovic, M.; Miller, G. J.; Chakrabarti, R. R.; North, W. 
R.; Haines, A. P.; Stirling, Y.; Imeson, J. D.; Thompson, S. G. "Haemostatic function 
and ischaemic heart disease: principal results of the Northwick Park Heart Study." 
Lancet 1986, 2, 533-537. 
 
(7) Meade, T. W.; North, W. R.; Chakrabarti, R.; Stirling, Y.; Haines, A. P.; Thompson, 
S. G.; Brozovie, M. "Haemostatic function and cardiovascular death: early results of a 
prospective study." Lancet 1980, 1, 1050-1054. 
 
(8) Tang, L.; Eaton, J. W. "Fibrin(ogen) mediates acute inflammatory responses to 
biomaterials." J Exp Med 1993, 178, 2147-2156. 
 
(9) Tang, L.; Hu, W.-J. "Molecular determinants of biocompatibility." Expert Rev. Med. 
Devices 2005, 2, 493-500. 
 
(10) Tang, L.; Ugarova, T. P.; Plow, E. F.; Eaton, J. W. "Molecular determinants of acute 
inflammatory responses to biomaterials." J Clin Invest 1996, 97, 1329-1334. 
 
(11) Brash, J.; Horbett, T. Proteins at Interfaces II:fundamentals and applications. 
American Chemical Society: 1995; p 1-23. 
 
(12) Andrade, J.; Hlady, V. Blood in contact with natural and artificial surfaces. The New 
York Academy of Sciences: New York, 1987; Vol. 516, p 158-172. 
 
 20
(13) Jung, S.-Y.; Lim, S.-M.; Albertorio, F.; Kim, G.; Gurau, M. C.; Yang, R. D.; Holden, 
M. A.; Cremer, P. S. "The Vroman effect: A molecular level description of fibrinogen 
displacement." J. Am. Chem. Soc. 2003, 125, 12782-12786. 
 
(14) Horbett, T. A. "Principles underlying the role of adsorbed plasma proteins in blood 
interactions with foreign materials." Cardiovascular Pathology 1993, 2, 137S-148S. 
 
(15) Weisel, J. W. "Fibrinogen and fibrin." Adv Protein Chem 2005, 70, 247-299. 
 
(16) Mosesson, M.; Siebenlist, K. R.; Meh, D. A. "The structure and biological features of 
fibrinogen and fibrin." Ann. N.Y. Acad. Sci. 2001, 936, 11-30. 
 
(17) Mosesson, M. W. "Fibrinogen and fibrin polymerization and functions." Blood 
Coagulation and Fibrinolysis 1999, 10, S45-S48. 
 
(18) Henschen, A. "On the structure of functional sites in fibrinogen." Thromb. Res. 1983, 
Supplement V, 27-39. 
 
(19) Blomback, B. "Fibrinogen: Evolution of the structure-function concept." Ann. N.Y. 
Acad. Sci. 2001, 936, 1-10. 
 
(20) Litvinov, R. I.; Yakovlev, S.; Tsurupa, G.; Gorkun, O. V.; Medved, L.; Weisel, J. W. 
"Direct evidence for specific interactions of the fibrinogen alphaC-domains with the 
central E region and with each other." Biochemistry 2007, 46, 9133-9142. 
 
(21) Laurens, N.; Koolwijk, P.; de Maat, M. P. "Fibrin structure and wound healing." J 
Thromb Haemost 2006, 4, 932-939. 
 
(22) Hartford, O. M.; Wann, E. R.; Hook, M.; Foster, T. J. "Identification of residues in 
the Staphylococcus aureus fibrinogen-binding MSCRAMM clumping factor A (ClfA) 
that are important for ligand binding." J Biol Chem 2001, 276, 2466-2473. 
 
(23) Hawiger, J.; Kloczewiak, M.; Timmons, S.; Strong, D.; Doolittle, R. F. "Interaction of 
fibrinogen with staphylococcal clumping factor and with platelets." Ann N Y Acad Sci 
1983, 408, 521-535. 
 
(24) Lundblad, R. L.; Kingdon, H. S.; Mann, K. G. "Thrombin." Methods in Enzymology 
1976, 45, 156-176. 
 
(25) Goldsack, N. R.; Chambers, R. C.; Dabbagh, K.; Laurent, G. J. "Thrombin." Int J 
Biochem Cell Biol 1998, 30, 641-646. 
 
(26) Pechik, I.; Madrazo, J.; Mosesson, M. W.; Hernandez, I.; Gilliland, G. L.; Medved, L. 
"Crystal structure of the complex between thrombin and the central "E" region of 
fibrin." Proc Natl Acad Sci U S A 2004, 101, 2718-2723. 
 
 21
(27) Rose, T.; Cera, E. D. "Three-dimensional modeling of thrombin-fibrinogen 
interaction." J. Biol. Chem. 2002, 277, 18875-18880. 
 
(28) Binnie, C. G.; Lord, S. T. "The fibrinogen sequences that interact with thrombin." 
Blood 1993, 81, 3186-3192. 
 
(29) Blomback, B. "Fibrin formation in whole blood." Thromb Res 2000, 99, 307-310. 
 
(30) Weisel, J. W. "Fibrin assembly. Lateral aggregation and the role of the two pairs of 
fibrinopeptides." Biophys J 1986, 50, 1079-1093. 
 
(31) Veklich, Y.; Ang, E. K.; Lorand, L.; Weisel, J. W. "The complementary aggregation 
sites of fibrin investigated through examination of polymers of fibrinogen with 
fragment E." Proc. Natl, Acad. Sci. 1998, 95, 1438-1442. 
 
(32) Weisel, J. W.; Nagaswami, C. "Computer modeling of fibrin polymerization kinetics 
correlated with electron microscope and turbidity observations: clot structure and 
assembly are kinetically controlled." Biophys J 1992, 63, 111-128. 
 
(33) Weisel, J. W.; Veklich, Y.; Gorkun, O. "The sequence of cleavage of fibrinopeptides 
from fibrinogen is important for protofibril formation and enhancement of lateral 
aggregation in fibrin clots." J Mol Biol 1993, 232, 285-297. 
 
(34) Shainoff, J. R.; Dardik, B. N. "Fibrinopeptide B in fibrin assembly and metabolism: 
physiologic significance in delayed release of the peptide." Ann N Y Acad Sci 1983, 
408, 254-268. 
 
(35) Mosesson, M. W.; DiOrio, J. P.; Muller, M. F.; Shainoff, J. R.; Siebenlist, K. R.; 
Amrani, D. L.; Homandberg, G. A.; Soria, J.; Soria, C.; Samama, M. "Studies on the 
ultrastructure of fibrin lacking fibrinopeptide B (beta-fibrin)." Blood 1987, 69, 1073-
1081. 
 
(36) Bell, S. E.; Shah, C. M.; Gordge, M. P. "Protein disulfide-isomerase mediates 
delivery of nitric oxide redox derivatives into platelets." Biochem J 2007, 403, 283-
288. 
 
(37) Hothersall, J. S.; Noronha-Dutra, A. A. "Nitrosothiol processing by platelets." 
Methods Enzymol 2002, 359, 238-244. 
 
(38) Gordge, M. P.; Hothersall, J. S.; Noronha-Dutra, A. A. "Evidence for a cyclic GMP-
independent mechanism in the anti-platelet action of S-nitrosoglutathione." Br J 
Pharmacol 1998, 124, 141-148. 
 
(39) Simon, D. I.; Stamler, J. S.; Jaraki, O.; Keaney, J. F.; Osborne, J. A.; Francis, S. A.; 
Singel, D. J.; Loscalzo, J. "Antiplatelet properties of protein S-nitrosothiols derived 
 22
from nitric oxide and endothelium-derived relaxing factor." Arterioscler Thromb 
1993, 13, 791-799. 
 
(40) Radomski, M. W.; Rees, D. D.; Dutra, A.; Moncada, S. "S-nitroso-glutathione inhibits 
platelet activation in vitro and in vivo." Br J Pharmacol 1992, 107, 745-749. 
 
(41) Mellion, B. T.; Ignarro, L. J.; Myers, C. B.; Ohlstein, E. H.; Ballot, B. A.; Hyman, A. 
L.; Kadowitz, P. J. "Inhibition of human platelet aggregation by S-nitrosothiols. 
Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic 
GMP accumulation." Mol Pharmacol 1983, 23, 653-664. 
 
(42) Mihalyi, E. "Clotting of bovine fibrinogen. Calcium binding to fibrin during clotting 
and its dependence on release of fibrinopeptide B." Biochemistry 1988, 27, 967-976. 
 
(43) Procyk, R.; Blomback, B. "Disulfide bond reduction in fibrinogen: calcium protection 
and effect on clottability." Biochemistry 1990, 29, 1501-1507. 
 
(44) Hardy, J. J.; Carrell, N. A.; McDonagh, J. "Calcium ion functions in fibrinogen 
conversion to fibrin." Ann N Y Acad Sci 1983, 408, 279-287. 
 
(45) Griaznukhina, E. A. "Effect of calcium, ionic strength and temperature on the 
enzymatic phase of fibrinogen conversion to fibrin." Ukr Biokhim Zh 1964, 36, 898-
906. 
 
(46) Undas, A.; Brummel-Ziedins, K. E.; Mann, K. G. "Antithrombotic properties of 
aspirin and resistance to aspirin: beyond strictly antiplatelet actions." Blood 2007, 
109, 2285-2292. 
 
(47) Al-Sa'doni, H. H.; Ferro, A. "S-nitrosothiols as nitric oxide-donors: chemistry, 
biology and possible future therapeutic applications." Curr Med Chem 2004, 11, 
2679-2690. 
 
(48) Hogg, N. "Biological chemistry and clinical potential of S-nitrosothiols." Free Radic 
Biol Med 2000, 28, 1478-1486. 
 
(49) Williams, D. L. H. "The Chemistry of S-Nitrosothiols." Acc. Chem. Res. 1999, 32, 
869-876. 
 
(50) Akhter, S.; Vignini, A.; Wen, Z.; English, A.; Wang, P. G.; Mutus, B. "Evidence for 
S-nitrosothiol-dependent changes in fibrinogen that do not involve transnitrosation or 
thiolation." Proc Natl Acad Sci U S A 2002, 99, 9172-9177. 
 
(51) Wring, S. A.; Hart, J. P.; Birch, B. J. "Determination of glutathione in human plasma 
using high-performance liquid chromatography with electrochemical detection with a 
carbon-epoxy resin composite electrode chemically modified with cobalt 
phthalocyanine." Analyst 1989, 114, 1571-1573. 
 23
 
(52) Anderson, M. E.; Meister, A. "Dynamic state of glutathione in blood plasma." J Biol 
Chem 1980, 255, 9530-9533. 
 
(53) Dogru-Abbasoglu, S.; Mutlu-Turkoglu, U.; Turkoglu, S.; Erbil, Y.; Barbaros, U.; 
Uysal, M.; Aykac-Toker, G. "Glutathione S-transferase-pi in malignant tissues and 
plasma of human colorectal and gastric cancers." J Cancer Res Clin Oncol 2002, 128, 
91-95. 
 
(54) Lane, J. D.; Opara, E. C.; Rose, J. E.; Behm, F. "Quitting smoking raises whole blood 
glutathione." Physiol Behav 1996, 60, 1379-1381. 
 
(55) Gorbet, M. B.; Sefton, M. V. "Biomaterial-associated thrombosis: roles of 
coagulation factors, complement, platelets and leukocytes." Biomaterials 2004, 25, 
5681-5703. 
 
(56) Tang, L.; Eaton, J. W. "Inflammatory responses to biomaterials." Am J Clin Pathol 
1995, 103, 466-471. 
 
(57) Agnihotri, A.; Christopher A, S. "Time-dependent conformational changes in 
fibrinogen measured by atomic force microscopy." Langmuir 2004, 20, 8864-8852. 
 
(58) Cacciafesta, P.; Hallam, K. R.; Watkinson, A. C.; Allen, G. C.; Miles, M. J.; Jandt, K. 
D. "Visualization of human plasma fibrinogen adsorped on titanium implant surfaces 
with different roughness." Surf. Sci. 2001, 491, 405-420. 
 
(59) Cacciafesta, P.; Humphris, A. D. L.; Jandt, K. D.; Miles, M. J. "Human plasma 
fibrinogen adsorption on ultraflat titanium oxide surfaces studied with atomic force 
microscopy." Langmuir 2000, 16, 8167-8175. 
 
(60) Dyr, J. E.; Tichy, I.; Jirouskova, M.; Tobiska, P.; Slavik, R.; Homola, J.; Brynda, E.; 
Houska, M.; Suttnar, J. "Molecular arrangement of adsorbed fibrinogen molecules 
characterized by specific monoclonal antibodies and a surface plasmon resonance 
sensor." Sens, Acutators, B 1998, 51, 268-272. 
 
(61) Hemmerle, J.; Altmann, S. M.; Maaloum, M.; Horber, J. K. H.; Heinrich, L.; Voegel, 
J. C.; Schaaf, P. "Direct observation of the anchoring process during the adsorption of 
fibrinogen on a solid surface by force-spectroscopy mode atomic force microscopy." 
Proc. Natl, Acad. Sci. 1999, 96, 6705-6710. 
 
(62) Holland, N. B.; Marchant, R. E. "Individual plasma proteins detected on rough 
biomaterials by phase imaging AFM." J. Biomed. Mater. Res. 2000, 51, 307-315. 
 
(63) Marchin, K. L.; Berrie, C. L. "Conformational changes in the plasma protein 
fibrinogen upon adsorption to graphite and mica investigated by atomic force 
microscopy." Langmuir 2003, 19, 9883-9888. 
 24
 
(64) Retzinger, G. S.; Cook, B. C.; DeAnglis, A. P. "The binding of fibrinogen to surfaces 
and the identification of two distinct surface-bound species of the protein." Journal of 
Colloid and Interface Science 1994, 168, 514-521. 
 
(65) Evans-Nguyen, K. M.; Schoenfisch, M. H. "Fibrin proliferation at model surfaces: 
influence of surface properties." Langmuir 2005, 21, 1691-1694. 
 
(66) Cook, B. C. "Reactivity of human platelets with immobilized fibrinogen is dictated by 
the chemical character of the surface." Thromb. Res. 2001, 104, 39-48. 
 
(67) Lindon, J. N.; McManama, G.; Kushner, L.; Merrill, E. W.; Salzman, E. W. "Does the 
conformation of adsorbed fibrinogen dictate platelet interactions with artificial 
surfaces?" Blood 1986, 68, 355-362. 
 
(68) Rysava, J.; Dyr, J. E.; Homola, J.; Dostalek, J.; Krizova, P.; Masova, L.; Suttnar, J.; 
Briestensky, J.; Santar, I.; Myska, K.; Pecka, M. "Surface interactions of oxidized 
cellulose with fibrin(ogen) and blood platelets." Sensors and Actuators, B: Chemical 
2003, B90, 243-249. 
 
(69) Radomski, M. W.; Palmer, R. M. J.; Moncada, S. "The role of nitric oxide and cGMP 
in platelet adhesion to vascular endothelium." Biochem. Biophys. Res. Commun. 
1987, 148, 1482-1489. 
 
(70) Shahbazi, T.; Jones, N.; Radomski, M. W.; Moro, M. A.; Gingell, D. "Nitric oxide 
donors inhibit platelet spreading on surfaces coated with fibrinogen but not with 
fibronectin." Thrombosis Research 1994, 75, 631-642. 
 
(71) Salzman, E. W.; Lindon, J.; McManama, G.; Ware, A. J. Role of fibrinogen in 
activation of platelets by artificial surfaces. In Blood in Contact with Natural and 
Artificial Surfaces, Leonard, E. F.;Turitto, V. T.;Vroman, L., Eds. The New York 
Academy of Sciences: New York, 1987; Vol. 516, pp 184-195. 
 
(72) Anderson, J. M.; Kottke-Marchant, K. "Platelet interactions with biomaterials and 
artificial devices." CRC Crit. Rev. Biocompat. 1985, 1, 111-204. 
 
(73) Tomikawa, M.; Iwamoto, M.; Olsson, P.; Soederman, S.; Blombaeck, B. "On the 
platelet-fibrinogen interaction." Thrombosis Research 1980, 19, 869-876. 
 
(74) Endenburg, S. C.; Hantgan, R. R.; Sixma, J. J.; de Groot, P. G.; Zwaginga, J. J. 
"Platelet adhesion to fibrin(ogen)." Blood Coagul Fibrinolysis 1993, 4, 139-142. 
 
(75) Tsai, W. B.; Grunkemeier, J. M.; Horbett, T. A. "Human plasma fibrinogen 
adsorption and platelet adhesion to polystyrene." J Biomed Mater Res 1999, 44, 130-
139. 
 
 25
(76) Sit, P. S.; Marchant, R. E. "Surface-dependent differences in fibrin assembly 
visualized by atomic force microscopy." Surf. Sci. 2001, 491, 421-432. 
 
(77) Sit, P. S.; Marchant, R. E. "Surface-dependent conformations of human fibrinogen 
observed by atomic force microscopy under aqueous conditions." Thromb. 
Haemostasis 1999, 82, 1053-1060. 
 
(78) Liu, W. J., L.M.; Sparks, E.A.; Falvo, M.R.; Hantgan, R.R.; Superfine, R.; Lord, S.T.; 
Guthold, M. "Fibrin fibers have extraordinary extensibility and elasticity." Science 
2006, 313, 634. 
 
(79) Brown, A. E.; Litvinov, R. I.; Discher, D. E.; Weisel, J. W. "Forced unfolding of 
coiled-coils in fibrinogen by single-molecule AFM." Biophys J 2007, 92, L39-41. 
 
(80) Fisher, T. E.; Oberhauser, A. F.; Carrion-Vazquez, M.; Marszalek, P. E.; Fernandez, 
J. M. "The study of protein mechanics with the atomic force microscope." Trends in 
Biochemical Sciences 1999, 24, 379-384. 
 
(81) Levy, R.; Maaloum, M. "Specific molecular interactions by force spectroscopy: From 
single bonds to collective properties." Biophysical Chemistry 2005, 117, 233-237. 
 
(82) Clausen-Schaumann, H.; Seitz, M.; Krautbauer, R.; Gaub, H. E. "Force spectroscopy 
with single bio-molecules." Current Opinion in Chemical Biology 2000, 4, 524-530. 
 
(83) Heinz, W. F.; Hoh, J. H. "Spatially resolved force spectroscopy of biological surfaces 
using the atomic force microscope." Trends in Biotechnology 1999, 17, 143-150. 
 
(84) Zlatanova, J.; Lindsay, S. M.; Leuba, S. H. "Single molecule force spectroscopy in 
biology using the atomic force microscope." Progress in Biophysics and Molecular 
Biology 2000, 74, 37-61. 
 
(85) Geer, C. B.; Tripathy, A.; Schoenfisch, M. H.; Lord, S. T.; Gorkun, O. V. "Role of 
"B-b" knob-hole interactions in fibrin binding to adsorbed fibrinogen." J Thromb 
Haemost 2007. 
 
(86) Geer, C. B.; Rus, I. A.; Lord, S. T.; Schoenfisch, M. H. "Surface-dependent 
fibrinopeptide A accessibility to thrombin." Acta Biomater 2007, 3, 663-668. 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
ROLE OF “B-b” KNOB-HOLE INTERACTIONS IN FIBRIN BINDING TO ADSORBED 
FIBRINOGEN 
 
 
2.1 Introduction                                                                          
    One of the most abundant proteins in blood, fibrinogen plays a pivotal role in hemostasis 
by sealing vessel ruptures and promoting wound healing (1).  Following vessel injury, 
soluble fibrinogen is converted to an insoluble fibrin polymer matrix.  This conversion occurs 
in three steps:  thrombin catalysis leading to the formation of fibrin monomers; assembly of 
fibrin monomers into half-staggered, double-stranded protofibrils; and, assembly of multiple 
protofibrils into branched, thick fibers [for review see (2)].  The fibrinogen molecule consists 
of three pairs of non-identical polypeptide chains Aα, Bβ, and γ linked together by 29 
disulfide bonds (3). Fibrinogen chains are folded into three distinct structural regions, two 
distal D regions linked by coiled-coil connectors to one central E region (Fig. 2.1A). Each D 
region contains polymerization holes “a” and “b” located in the C terminus of the γ and Bβ 
chains, respectively (4-6). The central E region contains two sets of “A” and “B” 
polymerization knobs that are hidden in fibrinogen (7). The knobs become exposed only 
when fibrinogen is transformed into fibrin monomer by the serine protease thrombin. 
Thrombin cleaves fibrinopeptides A (FpA) and B (FpB) from the N-terminus of fibrinogen’s 
Aα and Bβ chains, respectively (8). The newly exposed polymerization knobs of one fibrin 
monomer interact with corresponding holes of another fibrin monomer or fibrinogen through 
“A-a” and “B-b” knob-hole interactions (9-12). 
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Figure 2.1  A. Schematic representation of fibrinogen; the E and D structural regions and 
polymerization holes are indicated by arrows, fibrinopeptides A and B (FpA and FpB) are 
depicted as spheres. B. Fibrin fragments without (NDSK) and with exposure of 
polymerization knobs A (desA-NDSK) or A and B (desAB-NDSK). 
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    Thrombin cleaves FpA faster than FpB, so thrombin-catalyzed protofibrils are formed 
predominantly via “A-a” interactions (13-15). Nevertheless, studies with snake venom 
enzymes that remove either FpA or FpB have demonstrated that fibrin clots can be formed by 
either “A-a” or “B-b” interactions, indicating both interactions can mediate protofibril 
formation (15-20). Experiments with a variant recombinant fibrinogen showed that “B-b” 
interactions may play a substantial role in protofibril formation when “A-a” interactions are 
weakened (21). On the other hand, non-equilibrium based laser tweezers studies by Weisel 
and co-workers demonstrated only “A-a” interactions occur during the binding of fibrin 
fragments to fibrinogen molecules even when both “B” knobs and holes “b” are available 
(22). In similar experiments, “B-b” knob-hole interactions were apparent only when “A-a” 
interactions were excluded by experimental design (23). While it was shown that “B-b” 
interactions contribute to overall fibrin clot stability (17, 24), the question remains whether 
“B-b” interactions occur within protofibrils alongside “A-a” interactions or between 
protofibrils.  
    The work presented in this chapter was designed to measure the strength of “A-a” 
interactions under equilibrium conditions and clarify the role of “B-b” interactions. Surface 
plasmon resonance (SPR) was used to determine the affinity constants of individual knob-
hole interactions without interference from other parts of the fibrin molecule that may 
contribute to polymerization, notably the αC domain and D-D interface (12, 25-27).  The 
binding of fibrin fragments containing either “A” or “A” and “B” knobs (desA-NDSK or 
desAB-NDSK) was measured to the holes in fibrinogen adsorbed on a hydrophobic surface. 
Inhibition experiments were also performed by specifically blocking the holes “a” and/or “b” 
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with peptides to determine whether “B-b” interactions occur simultaneously to “A-a” 
interactions within the same pair of interacting molecules. 
 
2.2 Experimental Methods 
    2.2.1 Materials.  All reagents were of analytical grade and purchased from Sigma (St. 
Louis, MO) unless noted otherwise. Human plasma fibrinogen (FIB 1) and α-thrombin (HT 
2970PA) were purchased from Enzyme Research Laboratories (Southbend, IN). Batroxobin 
(batroxobin moojeni) was obtained from CenterChem (Stamford, CT). Peptides GPRP amide 
and GHRP amide were purchased from Bachem USA (Torrance, CA) and Biopeptide Co. 
(San Diego, CA).  Peptide AHRPY amide (28) was synthesized by the Protein Chemistry 
Core Facility at the University of North Carolina at Chapel Hill.   
     
    2.2.2 Fibrinogen and NDSK preparation.  Fibrinogen was dialyzed against 20 mM 
HEPES, pH 7.4, 150 mM NaCl, 1 mM CaCl2 buffer (HBSC), stored at -80 °C, thawed at 37 
°C for 10 min and maintained at ambient temperature. Fibrinogen concentration was 
determined using an extinction coefficient of 1.51 at 280 nm for a 1 mg/mL solution (13).  
We prepared three different forms of NDSK fragments (Fig. 2.1B) based on described 
procedures  (29, 30). Fibrin clots were formed by adding thrombin (1 U/ml) or batroxobin (1 
BU/mL) to fibrinogen (10 mg/mL) and incubating for 24 h. The fibrin clot or fibrinogen (10 
mg/ml) was dissolved in 70% formic acid and reacted with CNBr (1/1.5, w/w, protein/CNBr 
ratio). The reaction continued for 24 h at ambient temperature under nitrogen.  Following 
dialysis against 5% acetic acid and 100 mM NaCl, NDSK was purified from the fibrinogen, 
desA-NDSK batroxobin-generated fibrin, and desAB-NDSK thrombin-generated fibrin. Each 
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fragment was purified by size-exclusion chromatography using two sequentially connected 
Superdex 200 prep grade HR16/50 columns (Pharmacia, Uppsala, Sweden), equilibrated with 
5% acetic acid and 100 mM NaCl. Fragment fractions were pooled, concentrated using a 30 
kDa molecular mass cutoff centrifugal filter device (Millipore, Bedford, MA), dialyzed 
against 20 mM HEPES, pH 7.4, 150 mM NaCl buffer (HBS) and stored at -80 °C. The 
fragment concentrations were determined from the absorbance at 280 nm using the 
theoretical extinction coefficients for 1 mg/mL solutions, 0.74 for NDSK (Mr = 59 kDa), 
0.78 for desA-NDSK (Mr = 56 kDa), and 0.82 for desAB-NDSK (Mr = 53 kDa). 
    
     2.2.3 Polyacrylamide gel electrophoresis (PAGE).  Native and SDS electrophoresis was 
performed with an automated PHAST system (Pharmacia, Uppsala, Sweden), using the same 
8-25% gradient polyacrylamide gels. Native gels were run using 0.25 M Tris, 0.88 M L-
alanine pH 8.8 buffer for 280 Vh. SDS gels were run using 0.20 M Tricine, 0.20 M Tris, pH 
8.1, 0.55% SDS buffer system for 76 Vh. Protein bands were visualized with Coomassie 
R250. 
    
     2.2.4 Analytical ultracentrifugation.  Sedimentation equilibrium experiments were 
performed using a Beckman Optima XL-I analytical ultracentrifuge with a Ti50 8-hole rotor 
and six-sectored centerpieces. Samples of NDSK, desA-NDSK and desAB-NDSK (three 
different concentrations of each fragment at 0.25, 0.50, and 0.75 ABS280) were spun at 
10,000 rpm or at 13,000 rpm for 18 h at 25 °C. Absorbance scans at 280 nm were recorded 
every 2 h.  Equilibrium was assumed when the difference between two consecutive 
absorbance profiles became zero. The meniscus-depletion method was employed to 
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determine the absorbance offsets after over-speeding the samples at 25,000 rpm for 6 h. 
Equilibrium absorbance profiles were analyzed using Beckman XL-A/XL-I Analysis 
Software Version 4.0 and fit using both a single-species and a monomer-dimer model based 
on the Lamm equation (31). Experiments with NDSK and desA-NDSK were performed 
twice, and the equilibrium constants averaged.  The desAB-NDSK experiment was 
performed once.   
     
    2.2.5 Surface plasmon resonance (SPR).  SPR sensorchips were prepared in house for use 
with a Biacore X (Biacore, Inc., Uppsala, Sweden) instrument using glass cover slips 
(Electron Microscopy Sciences, Washington, PA) modified with hydrophobic self-assembled 
monolayers (SAMs), as described previously (32). The HBSC flow rate was a constant 10 
µL/min and a continuous flow of 25 °C buffer was maintained through the instrument at all 
times. After reaching a stable baseline (drift < 1 response unit/min), 1 mg/mL fibrinogen in 
HBSC was flowed over the sensorchip surface for 600 s, the chip rinsed with HBSC for 300 s 
and then washed three times using the manufacturer’s “wash” command over an additional 
300 s. The NDSK, desA-NDSK or desAB-NDSK samples were injected over the thoroughly 
rinsed adsorbed fibrinogen and the association/dissociation profiles were monitored for 600 
s.  Notably, we used 1 mg/mL fibrinogen to generate a closely-spaced monolayer of protein, 
minimizing conformational changes observed with monolayers formed from dilute solutions 
(33, 34)).  The desA- and desAB-NDSK binding was measured 600 s after completion of the 
fragment injection to avoid the complications associated with measuring and subtracting bulk 
refractive index shifts.  Thus, steady-state measurements rather than kinetic analyses were 
used to determine equilibrium binding constants.   
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    To obtain binding curves, fibrinogen deposition and fragment binding were repeated for a 
range of concentrations of desA-NDSK or desAB-NDSK fragments using a new sensorchip 
for each experiment. Profiles were normalized with respect to the amount of fibrinogen 
deposited during each binding experiment, correcting the SPR signal for the molecular mass 
difference of the fragments compared to fibrinogen. Experiments were designed to be 
independent of the concentration of fibrinogen molecules capable of binding fragments, 
which we assumed to be reproducible from sensorchip to sensorchip. The reproducibility of 
our data supported this assumption. The resulting normalized signal was expressed in units of 
binding ratios, representing an average number of fragment molecules bound per fibrinogen 
molecule. For desAB-NDSK, the normalized binding response was plotted against fragment 
concentration to generate a binding curve.  For desA-NDSK, which exists in a monomer-
dimer equilibrium in solution, the ratio of monomers to dimers was calculated at each desA-
NDSK concentration using the centrifugation data and adjusted the total SPR signal for the 
binding of dimers to the adsorbed fibrinogen. The mass contribution of the second molecule 
in the dimer, which we assumed does not directly interact with adsorbed fibrinogen and 
therefore does not contribute to the affinity of desA-NDSK for fibrinogen, was subtracted 
from the total fragment binding. The resulting signal was the mass response of the monomers 
and one molecule of the dimer pair that was interacting directly with adsorbed fibrinogen. 
The final corrected signal from desA-NDSK molecules directly interacting with fibrinogen 
was plotted against fragment concentration to generate a binding curve.  Peptide competition 
experiments were performed in triplicate using GPRP, GHRP and AHRPY by incubating 25 
µM desA-NDSK or desAB-NDSK with 4 mM of one or two peptides prior to injection over 
adsorbed fibrinogen. 
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2.3 Results 
    2.3.1 Purification of NDSK, desA-NDSK, and desAB-NDSK fragments.  The NDSK 
fragment of fibrinogen is composed of two copies each of Aα1-51, Bβ1-118, and γ1-78, all 
joined by 11 disulfide bonds. NDSK, containing intact FpA and FpB and thus no exposed 
polymerization knobs, was purified from a CNBr digest of fibrinogen. The fragments desA-
NDSK containing polymerization knobs “A” and desAB-NDSK containing polymerization 
knobs “A” and “B” were purified from the CNBr digest of desA- and desAB-fibrin, 
respectively.  The ligand fragments, depicted in Figure 2.1B, were generated and purified as 
described in methods.  A representative chromatogram of NDSK fragment purification is 
shown in Figure 2.2.  The reaction conditions generated two products, which appeared as a 
closely spaced doublet in SDS-PAGE (for NDSK, the two top-most bands in Fig. 2.2 insert, 
indicated by the arrow in CNBr digest lane). Increasing the digest time (up to 48 h) or 
concentration of CNBr (up to 1/5, w/w, protein/CNBr ratio) did not change the appearance or 
yield of the NDSK species. Notably, doublets were present in the CNBr digests of 
fibrinogen, desA- and desAB-fibrin clots. The two products (Fig. 2.2 insert, NDSK lane) 
were resolved using size exclusion chromatography and, for all experiments, we used the 
form with the lower apparent molecular mass.  These fragments ran as single bands in SDS 
with an apparent molecular mass of ~ 67 kDa (Fig. 2.2, insert and Fig. 2.3B).  
     
    2.3.2 Characterization of NDSK fragments.  The NDSK fragments were analyzed by both 
native and denatured polyacrylamide gel electrophoresis (PAGE). While both NDSK and 
desAB-NDSK appeared as single bands on the native gel, the desA-NDSK fragment 
appeared as two bands suggesting the presence of a higher molecular mass species (Fig. 2.3).   
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Figure 2.2  Representative chromatogram of NDSK fragment purification using two 
sequentially connected Superdex 200 prep grade HR16/50columns. The position of the 
NDSK peak and the volume (mL) over which fragments were collected is identified by the 
horizontal bracket underneath the peak. The insert shows an 8-25% gradient SDS PAGE of 
the CNBr digest of fibrinogen with the NDSK bands denoted by an arrow and final purified 
NDSK fragment from the CNBr digest. The position of molecular mass markers (in kDa) is 
indicated on the right. 
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Figure 2.3  Polyacrylamide gel electrophoresis analysis of 2 µg NDSK (1), desA-NDSK (2), 
and desAB-NDSK (3) in a native 8-25% gradient polyacrylamide gel A. and in a denatured 
(SDS) 8-25% gradient polyacrylamide gel.  B. The position of the molecular mass markers 
(in kDa) for the denatured SDS gel is indicated at the side of panel B. 
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In contrast, all three fragments ran as single bands during SDS-PAGE, (Fig. 2.3B).  To 
characterize the fragments in solution, analytical ultracentrifugation experiments of NDSK, 
desA-NDSK, and desAB-NDSK in HBSC (Fig. 2.4), were performed as described in 
Experimental Methods.  The equilibrium absorbance profiles were analyzed using both a 
single-species and a monomer-dimer model based on the Lamm equation (31).  The best fit 
was obtained with a monomer-dimer model using the calculated molecular weights of 59 
kDa for NDSK, 56 kDa for desA-NDSK, and 53 kDa for desAB-NDSK monomers. From 
this fit, the equilibrium dissociation constants of complex formation were determined to be 
25 µM for NDSK, 12 µM for desA-NDSK, and 46 µM for desAB-NDSK. Thus, under the 
conditions of our SPR experiments up to 60% of the desA-NDSK molecules were dimers, 
while essentially all NDSK and desAB-NDSK molecules were monomers.  
 
   2.3.3 NDSK binding experiments.  Fragment binding to adsorbed fibrinogen was measured 
by surface plasmon resonance (SPR); a representative sensorgram is shown in Figure 2.5.  
Fibrinogen was adsorbed at the hydrophobic surface of the methyl-terminated SAM upon 
flowing 1 mg/mL fibrinogen over the SPR sensor chip surface (Fig. 2.5A). The adsorption of 
fibrinogen resulted in monolayer coverage of the surface with a protein density of 6.0 ± 0.9 × 
10-9 µg/µm2 calculated assuming 1 SPR response unit is equivalent to 1 pg/mm2 of protein 
surface coverage as described by Biacore. Because exposure of the adsorbed fibrinogen to an 
additional injection of 1 mg/mL fibrinogen did not result in additional adsorption (data not 
shown), the chip surface was assumed to be completely covered.  Fibrinogen desorption from 
the surface during subsequent buffer flow was minimal (Fig. 2.5B), indicating fibrinogen 
molecules adhered to the SAM rather than to one another.  
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Figure 2.4  Analytical ultracentrifugation sedimentation data for NDSK, desA- and desAB-
NDSK.  A. curve-fitting residuals and B. equilibrium absorbance profiles. 
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Figure 2.5  Representative SPR sensorgram of response unit changes observed during A. 
injection of 1 mg/mL fibrinogen, B. restoration of buffer flow, C. injection of 25 µM desAB-
NDSK and D. restoration of buffer flow. The maximum SPR response change for fibrinogen 
is identified by (▼) and for desAB-NDSK fragment by (▲). 
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To determine the affinity constants for knob-hole interactions, two different knob-
containing fragments were employed: desA-NDSK and desAB-NDSK.  The desA-NDSK 
fragment contained only the “A” knob, while the desAB-NDSK fragment contained both the 
“A” and “B” knobs. The binding of both knob containing fragments in solution to holes in 
immobilized fibrinogen was studied. Upon introduction of desAB-NDSK into the SPR flow 
cell, the fragment associated with the adsorbed fibrinogen as indicated by the increase in SPR 
response (Fig. 2.5C). After restoration of buffer flow (Fig. 2.5D) a continual, very small 
change in SPR response consistent with the slow dissociation of desAB-NDSK was 
observed. A similar profile for desA-NDSK binding to fibrinogen was observed. Fragment 
binding profiles were obtained over a concentration range of 0.1 to 22 µM for desAB-NDSK 
and 0.1 to 43 µM for desA-NDSK. The SPR responses were converted to binding ratios 
(average number of fragment molecules bound per fibrinogen molecule on the surface) using 
equation 2.1,  
[2.1] 
 
where fragment SPR response is that generated by the fragment bound to fibrinogen (▲ in 
Fig. 2.5); fibrinogen SPR response is that generated by the adsorption of fibrinogen (▼ in 
Fig. 2.5); Mr (fibrinogen) is the mass of fibrinogen (340 kDa); and, Mr (fragment) is the 
mass of each corresponding fragment (desA-NDSK = 56 kDa and desAB-NDSK = 53 kDa). 
Because the ultracentrifugation and native PAGE data showed the desA-NDSK fragment 
self-associates, a correction was applied to account for the mass contribution of desA-NDSK 
dimers. The binding ratios obtained from equation 1 were adjusted using equation 2.2. 
 
Binding Ratio
Fragment SPR response
Fibrinogen SPR response 
×
Mr (fibrinogen)
Mr (fragment)
=
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desA-NDSK 
Binding Ratio -
Adjusted desA-NDSK 
Binding Ratio =
2
% desA-NDSK 
dimer
desA-NDSK 
Binding Ratio ×
 
     [2.2]
  
The % desA-NDSK dimer was calculated for each desA-NDSK concentration using a dimer 
equilibrium dissociation constant of 12 µM. Finally, the desAB-NDSK binding ratios and 
desA-NDSK adjusted binding ratios were plotted as a function of desA- or desAB-NDSK 
concentration.  The resulting binding curve for each NDSK fragment is shown in Figure 2.6. 
The plotted data were fit using a single-site interaction binding model, equation 2.3, 
 
          [2.3] 
 
where Bmax is the maximum binding signal, Kd is the equilibrium dissociation constant, and 
[NDSK fragment] is the concentration of the injected fragment in µM.  Equilibrium 
dissociation constant values of 3.7 ± 0.7 µM for desAB-NDSK and 5.8 ± 1.1 µM for desA-
NDSK binding to fibrinogen were determined, which were not statistically different at the 
95% confidence level according to a two-sided unpaired t-test (p = 0.14). The maximum 
binding was 2.3 ± 0.1 for desA-NDSK and 1.6 ± 0.1 for desAB-NDSK (Fig. 2.6). 
    Additional SPR experiments were conducted to verify the specificity and evaluate the 
individual contributions of “A-a” and “B-b” interactions. First, the binding of the NDSK 
fragment with no active knobs was examined. At 50 µM the binding of NDSK was less than 
15% of the desA-NDSK binding at 43 µM (Fig. 2.7), demonstrating no significant binding in 
the absence of knobs. Peptide inhibitors of polymerization were employed to selectively 
inhibit either “A-a” (GPRP) or “B-b” (GHRP and AHRPY) interactions. DesA- or 
 
Binding Ratio
Bmax [NDSK fragment]
Kd + [NDSK fragment]
=
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Figure 2.6  Binding curves for A. desA-NDSK and B. desAB-NDSK binding to 1 mg/mL 
fibrinogen adsorbed to a hydrophobic-terminated self-assembled monolayer as determined by 
SPR. The solid curves are the best fits obtained using eq. 2.3. 
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Figure 2.7  Representative SPR sensorgrams showing the binding of A. 43 µM desA-NDSK 
(dashed line) and B. 50 µM NDSK (solid line) to adsorbed fibrinogen. 
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desAB-NDSK (25 µM) was incubated with the peptides, the mixture exposed to adsorbed 
fibrinogen, and the SPR signal assessed 1200 s after injection. When desAB-NDSK was 
incubated with GHRP and GPRP individually, the binding was decreased by 48 and 89%, 
respectively, compared to desAB-NDSK alone (Fig. 2.8A). Because crystallography studies 
showed GHRP can bind in both holes “a” and “b” (35), inhibition with AHRPY was also 
examined, which binds exclusively in hole “b”  (36).  The results with AHRPY were the 
same as with GHRP; desAB-NDSK binding decreased 52% compared to desAB-NDSK 
alone (Fig. 2.9).  When the equimolar mixture of GHRP and GPRP was incubated with 
desAB-NDSK the binding ratio fell below zero, likely due to both the loss of desAB-NDSK 
binding and a slight desorption of fibrinogen. The small decrease in SPR signal resulting 
from fibrinogen desorption was determined to be less than 2% over the course of each 
experiment and was not detectable for any of the other fragment/peptide mixtures because 
the increase in signal due to fragment binding obscured the decrease in signal due to 
fibrinogen desorption. Similar to desAB-NDSK with GPRP, an 84% decrease in binding was 
observed when desA-NDSK was incubated with GPRP (Fig. 2.8B). Incubation of desA-
NDSK with GHRP or AHRPY did not result in inhibition, but rather a slight increase in 
binding compared to desA-NDSK alone. Finally, the addition of an equimolar mixture of 
GHRP and GPRP to desA-NDSK resulted in an 89% decrease in desA-NDSK binding. 
Collectively, these results demonstrate that the binding of desA- and desAB-NDSK to 
fibrinogen is promoted by specific knob-hole interactions and that “B-b” knob-hole 
interactions contribute to the binding of desAB-NDSK to surface-bound fibrinogen. 
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Figure 2.8  Representative SPR sensorgrams showing the binding of A. 25 µM desAB-
NDSK (solid line) and B. 25 µM desA-NDSK (solid line), in the presence of 4 mM GHRP 
(dashed line), 4 mM GPRP (dotted line), and equimolar mixture (BOTH) of GHRP and 
GPRP (dashed and dotted line) to adsorbed fibrinogen. 
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Figure 2.9   Representative SPR sensorgrams showing the binding of A. 25 µM desA-NDSK 
and 4 mM AHRPY (dotted line) and B. 25 µM desAB-NDSK and 4 mM AHRPY (solid line) 
to adsorbed fibrinogen. 
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2.4 Discussion 
    The design of these experiments allowed measurement of the affinities for knob-hole 
interactions between two molecules (“A-a” alone or “A-a” and “B-b” together) in the 
absence of other interactions that occur during polymerization. Although the affinities 
determined herein (5.8 ± 1.1 µM and 3.7 ± 0.7 µM) were not significantly different from one 
another, the higher affinity for the desAB-NDSK suggests both “A-a” and “B-b” interactions 
contribute to the binding. This suggestion was confirmed by the peptide inhibition studies, 
which showed both knob-hole pairs participate in desAB-NDSK binding to immobilized 
fibrinogen. At least an 84% decrease in both desA- and desAB-NDSK binding to fibrinogen 
was observed in the presence of GPRP, demonstrating “A-a” interactions are important to the 
binding of both fragments. Moreover, GHRP and AHRPY competed solely with desAB-
NDSK, indicating that “B-b” interactions participate in desAB-NDSK but not desA-NDSK 
binding to immobilized fibrinogen.  Finally, the GHRP/GPRP mixture decreased desAB-
NDSK binding more than GPRP alone, as would be expected if “B-b” interactions 
contributed to this interaction.  Taken together these data strongly support the conclusion that 
“B-b” interactions participate in the binding of desAB-NDSK to immobilized fibrinogen.  
This finding differs from that obtained in recent laser tweezers studies where GPRP, but not 
GHRP, inhibited interactions between desAB-NDSK and fibrinogen (22).  “B-b” interactions 
were detected in laser tweezers experiments only under conditions where “A-a” interactions 
were impaired or excluded (23). The difference between the SPR results herein and the laser 
tweezers data likely reflects the inherent differences between the methods. For example, “B-
b” interactions may occur subsequent to “A-a” interactions and thus are not detected in the 
forced dissociations of the laser tweezers binding studies.  Alternatively, the nature of the 
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immobilized species, directly adsorbed fibrinogen in the SPR experiments or covalently 
immobilized fibrinogen in the laser tweezers experiments, may alter the availability of hole 
“b”. 
    The affinities determined in this chapter (5.8 ± 1.1 µM and 3.7 ± 0.7 µM for desA- and 
desAB-NDSK, respectively) are remarkably similar to those determined for fragment D 
binding to suspended desAB-fibrin fragments that were produced by sonication, 2.4 µM  
(37). This similarity suggests that the affinities determined by SPR are analogous to those 
found in solution.  Interactions between fibrinogen and suspended desAB-fibrin fragments 
were even stronger (e.g., 56 nM), as anticipated if one fibrinogen molecule binds to fibrin 
through multiple sites (i.e., the two D regions) (37).  Recently, Ugarova and colleagues 
determined a similar affinity (1.47 ± 0.26 µM) using SPR to measure soluble fibrinogen 
binding to covalently immobilized fibrin molecules (38).  The similarity of these 
measurements suggests that the studies described in this chapter measure the interactions that 
mediate fibrin monomer binding to a single D region of intact fibrinogen.  Other 
investigations have examined the individual “A-a” and “B-b” interactions using peptides that 
mimic the “A” and “B” knobs (i.e., GPRP and GHRP, respectively).  In the presence of 2 
mM calcium, Kd’s of 20 µM for GPRP and 16 µM for GHRP were found (39). These 
affinities are somewhat weaker than the affinities determined for the larger desA- and 
desAB-NDSK fragments, which likely reflects the entropy costs associated with restraining 
the conformations of the smaller molecules.  The values determined by SPR are rational 
when compared with the published data (19, 37, 39, 40), indicating the data reflect the 
affinities of the “A-a” and “B-b” interactions as they occur in fibrin polymers.   
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    The observation that desAB-NDSK binds fibrinogen through both “A-a” and “B-b” 
interactions infers that both sets of interactions may occur between the same two fibrin 
molecules in a polymer.  In other words, “A-a” and “B-b” interactions may both support 
protofibril formation.  A model where “B-b” interactions occur within protofibrils was also 
inferred from previous studies using recombinant fibrinogens with substitutions in the high-
affinity calcium binding site in γC (21, 41). Thrombin-catalyzed polymerization of these 
fibrinogens was severely impaired and this polymerization was abolished by GHRP.  
Furthermore, the batroxobin-catalyzed polymerization was undetectable.  Similarly, 
Okumura and co-workers have recently found that substitutions in hole “a” markedly impair 
thrombin-catalyzed polymerization and that this polymerization is abolished by GHRP.  
Also, the anchrod-catalyzed polymerization of these variants was undetectable (Okumura et 
al, personal communication).  Consideration of the SPR binding studies together with the 
polymerization of these variant fibrinogens indicates that 1) both “A-a” and “B-b” 
interactions can support protofibril formation; 2) “A-a” interactions are higher affinity than 
“B-b” and on their own can support nearly normal polymerization; and, 3)  “B-b” 
interactions are lower affinity than “A-a” but are sufficient to support delayed 
polymerization.   
     This work also revealed that desA-NDSK, and to a much lower degree NDSK and desAB-
NDSK, form dimers in solution. However, the dimerization of fragments does not preclude 
their binding to fibrinogen. This observation suggests that the desA-NDSK monomers 
comprising the dimer are connected via regions of the molecule that do not interfere with the 
“A” knob and subsequent “A-a” interactions.  A recent laser tweezers study which examined 
interactions between pairs of NDSK fragments indicated that FpB mediates desA-NDSK 
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dimerization.  These studies showed interactions between two desA-NDSK molecules.  The 
interactions were lost when FpB was removed from one of the molecules, indicating a 
dependence on fibrinopeptide B (30). The biological significance of desA-NDSK 
dimerization is currently unknown.   
     In conclusion, SPR binding studies showed that both “A-a” and “B-b” interactions 
participate in the binding of desAB-NDSK to fibrinogen, and that the affinity of desA-NDSK 
binding was not markedly different from desAB-NDSK binding.  As such, the “A-a” 
interactions are particularly strong.  Furthermore, the “B-b” interactions can occur alongside 
“A-a” interactions when both the “B” knob and “b” hole are available.  The SPR studies in 
this chapter were designed to model the very early stages of polymerization (i.e., interactions 
occurring between two molecules).  The detection of both “A-a” and “B-b” interactions 
occurring between the fibrin (desAB-NDSK) and fibrinogen molecule demonstrates “B-b” 
interactions may have a role in protofibril formation.   
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CHAPTER 3 
DEVELOPMENT OF AN ATOMIC FORCE MICROSCOPY METHOD TO 
INVESTIGATE FIBRIN-FIBRIN INTERACTIONS  
 
3.1 Introduction 
    Weisel and co-workers reported the use of laser tweezers force spectroscopy to investigate 
specific fibrin(ogen) interactions (1-3).  Individual “A-a” knob-hole interactions were 
detected between pedestals modified with desA- or desAB-fibrin and fibrinogen- or D 
fragment-modified latex beads.  In addition to a low-force population attributed to non-
specific interactions, the forced dissociation of these interactions showed a single rupture 
event of ~125 pN in magnitude (1).  In subsequent work, the same investigators employed 
variant fibrinogens and their fragments to reveal both “B-b” and “A-b” knob-hole 
interactions (2) and specific interactions between the N-terminus of the Bβ chain and the D, 
E, and αC regions of fibrinogen (3).  Notably weaker than “A-a” binding, these interactions 
exhibited a more complex pattern that was attributed to the rupture of multiple parallel 
interactions (e.g., two simultaneous “B-b” bond ruptures).  Therefore, the rupture force 
distribution displayed several force populations.  The absolute magnitude of the observed 
forces was highly dependent on experimental conditions, including the loading rate (force per 
unit time) applied to the bond during rupture.    
    Despite its use in the investigation of many of the specific interactions involved in fibrin 
formation, laser tweezers technology has several limitations.  First, the optical trap 
controlling the modified beads has a maximum strength of 200 pN, limiting the range of 
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detectable interactions.  Second, spatial resolution is only accurate to within a few 
nanometers, unlike the sub-nanometer resolution possible with AFM (4-8).  Consequently, 
mechanical behaviors of molecules such as molecular unfolding or stretching occuring on the 
Å to nm scale immediately preceding bond rupture are not resolved from the bond rupture 
itself using laser tweezers.  The primary motivation for using AFM to study fibrin 
interactions is to exploit the superior capabilities of the instrument to gain deeper insight into 
knob-hole interactions beyond the information provided by laser tweezers.  
    In this chapter, a method to study the rupture forces of specific fibrin-fibrin interactions 
was developed using AFM combined with fibrin(ogen) and some of its fragments.  The 
method allowed for the accurate measurement of specific fibrin(ogen) forces while 
eliminating nonspecific interactions.  The unrivalled capabilities of the AFM enabled an in 
depth analysis of knob-hole interactions, providing crucial insight into the complexity of 
these interactions unobservable with laser tweezers.  
 
3.2 Experimental Methods   
    3.2.1 Materials.  All reagents were of analytical grade and purchased from Sigma (St. 
Louis, MO) unless noted otherwise.  Human plasma fibrinogen (FIB 1) and α-thrombin (HT 
2970PA) were purchased from Enzyme Research Laboratories (Southbend, IN). Batroxobin 
(batroxobin moojeni) was obtained from Center Chem (Stamford, CT).  The amide peptide 
GPRP was synthesized by the Protein Chemistry Laboratory at the University of North 
Carolina at Chapel Hill (Chapel Hill, NC).  
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    3.2.2 Recombinant fibrinogen preparation. Normal (wild type) was obtained as described 
previously (9, 10).  Briefly, fibrinogen was expressed in Chinese Hamster Ovary cells (CHO) 
and purified using immunoaffinity chromatography on a column covalently modified with 
IF-1 monoclonal antibodies.  After purification, fibrinogen was dialyzed against 20 mM 
HEPES pH 7.4, 150 mM NaCl buffer (HBS) and stored at -80 0C.  
 
    3.2.3 NDSK fibrin(ogen) fragments preparation.  NDSK fragments represent the central 
region of fibrinogen (Fig. 3.1A) or fibrin and contain polymerization knobs.  Three types of 
fragments were purified from CNBr digests and are illustrated in Figure 3.1B: NDSK 
retaining both FpA and FpB (no knobs exposed) isolated from human plasma fibrinogen, 
desA-NDSK lacking FpA (“A” knobs exposed) isolated from fibrin polymerized by 
batroxobin, and desAB-NDSK lacking both FpA and FpB (“A” and “B” knobs exposed) 
isolated from fibrin polymerized by thrombin.  Briefly, CNBr digests of fibrinogen or fibrin 
were separated using size-exclusion chromatography on Superdex 200 column, (Amersham 
Biosciences, Piscataway, NJ) as described (3).  Purified NDSK fragments were characterized 
by SDS-PAGE, dialyzed extensively against HBS and stored at -80 °C. 
 
    3.2.4 DD fragment preparation.  The DD fragment of fibrinogen represents the cross-
linked dimer of two D fragments from the D regions of fibrin molecules (Fig. 3.1C).  Each D 
fragment contains both polymerization holes “a” and “b”. The DD fragment was purified 
from a FXIII ligated fibrin clot as described previously (11). Briefly, the clot was digested by 
trypsin covalently coupled to agarose beads (Pierce, Rockford, IL). Fragments were purified 
using affinity chromatography on an NH2-GPRPAA affinity column. After elution from the  
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Figure 3.1  Schematic representation of all proteins used in AFM measurements, not to 
scale. A. Fibrinogen molecule depicted with αC domains interacting with fibrinopeptide A 
and fibrinopeptide B.  Disulfide bond connecting the N terminus of the Aα chains denoted as 
S-S. Locations of polymerization holes “a” in γC module and “b” in the βC module indicated 
by arrows. B. Fragments consisting of the central part of fibrinogen (NDSK) and fibrin 
(desA- and desAB-NDSK) shown with both fibrinopeptides present (NDSK), fibrinopeptide 
A cleaved (desA-NDSK), and both fibrinopeptides cleaved (desAB-NDSK). C. 
Polymerization holes-containing fragments D and DD. The location of the DD interface 
containing interacting surfaces inaccessible to solvent is depicted by X in DD fragment. D. 
Schematic representation of “A-a” knob-hole interaction between desAB-NDSK (knob-
containing molecule) and fibrinogen (hole-containing molecule). 
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column, the DD fragment was washed with HBS, concentrated using a 50 kDa cut-off 
centrifugal filter device (Millipore, Bedford, MA) and stored at -80 °C.  
 
        3.2.5 Substrate surface preparation: gold-coating and SAM generation.  Two surfaces 
were modified for use throughout these experiments: glass microscope slides (Electron 
Microscopy Sciences, Washington, PA) for AFM substrates and DNP-S (Veeco Probes, 
Camarillo, CA) AFM cantilevers.  The cantilevers were rinsed with chloroform, dried with a 
gentle stream of nitrogen and ozone cleaned for 30 min using a BioForce TipCleaner (Ames, 
IA). Microscope slides were cleaned as described previously (12).  Both tips and slides were 
then coated with 3 nm of chromium and 45 nm of gold as described previously (12).  For 
covalent attachment of protein, a carboxylic acid terminated self-assembled monolayer 
(SAM) was formed by immersing the gold-coated tips and substrates in 11-
mercaptoundecanoic acid solution (2 mM in absolute ethanol) overnight immediately prior to 
use.  All substrates were rinsed with absolute ethanol and ultra-pure water, and dried with 
nitrogen prior to use. 
 
    3.2.6 Sample Preparation and Force Curve Collection: Strategy 1.  The ultimate designs 
of the specific methods in Strategy 1 were the result of several months of troubleshooting by 
Dr. Ryan Fuierer and Dr. Oleg Gorkun prior to my involvement in this project.  To initiate 
covalent attachment of the proteins, the carboxylic acid-terminated surfaces were activated 
using a standard amine coupling method.  The AFM tip and substrate were exposed to equal 
volumes of 0.1 M N-hydroxysuccinimide (NHS) and 0.4 M 1-Ethyl-3-
(3dimethylaminopropyl) carbodiimide (EDC) (Pierce; Rockford, Il) in water for 30 min and 
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then rinsed with water.  Next, 0.15 mg/mL of protein was incubated with the tip and the 
substrate.  DesA-NDSK, desAB-NDSK or recombinant fibrinogen was attached to the tip and 
D fragment, DD fragment, BSA or recombinant fibrinogen was immobilized on the substrate.  
After the 10 min protein incubation, both surfaces were rinsed with AFM buffer (20 mM 
HEPES, 150 mM NaCl, 3 mM CaCl2, 2 mg/ml BSA, 0.1% Triton X-100, pH 7.4) to block 
any remaining activated surface groups with BSA and to remove loosely adhered protein.   
    All force measurements were made in AFM buffer using a Molecular Force Probe 3D from 
Asylum Research (Santa Barbara, CA) controlled with Igor Pro 5.03B (Wavemetrics; Lake 
Oswego, OR).  The substrate and tip were placed in the instrument and equilibrated in AFM 
buffer for ~2 h or until the signal deflection was stable.  The laser spot was positioned just 
slightly off center from the apex of the “D” triangular cantilever (nominal spring constant of 
60 pN/nm) prior to equilibration.  Force curves were collected at no less than 3 randomly 
chosen spots for each substrate, and 500 to 1000 curves were collected at each spot.  The 
approach/retract velocity was constant at 1800 nm/s and the initial trigger was set to 3 nm 
with a 500 nm force distance.  The spring constant of the cantilever was measured via the 
thermal method after the signal deflection stabilized.  The spring constant was measured at 
least 3 times per cantilever and the average value used in the force calculations and data 
analyses.    
 
    3.2.7 Sample Preparation and Force Curve Collection: Strategy 2.  Based on numerous 
discussions with expert force spectroscopists at Duke University and preliminary data 
generated by Laurel Averett, several modifications were implemented to the protein 
immobilization methods and force curve collection procedure described in section 3.2.6.  The 
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tip protein concentration was decreased from 0.15 mg/mL to 0.075 mg/mL for the desA-
NDSK, desAB-NDSK and fibrinogen.  The protein concentrations for the substrate were 
decreased from 0.15 mg/mL to 0.075 mg/mL, but D fragment, DD fragment or fibrinogen 
was mixed with an equal volume of 0.075 mg/mL BSA prior to immobilization.  Therefore, 
the final protein concentrations were 0.038 mg/mL of D fragment, DD fragment or fibrinogen 
and 0.038 mg/mL BSA, hereafter referred to as 50% solutions of active protein.  Also, the 
salt concentration was increased to 35 mM HEPES, 225 mM NaCl, 7.5 mM CaCl2 during the 
substrate protein immobilization step.  As with strategy 1, the proteins were incubated with 
the NHS/EDC-activated tip and substrate for 10 min and remaining active sites were blocked 
with BSA by rinsing the surfaces with AFM buffer.  However, an additional 10 min 
incubation step with AFM buffer was included.  Furthermore, a stringent washing procedure 
was developed to remove non-covalently attached proteins.  The protein-modified surfaces 
were rinsed alternately and incubated for 1 min each with a high salt (50 mM HEPES, 1 M 
NaCl, pH 7.4) and low pH buffer (50 mM NaOAc, 300 mM NaCl, pH 4.0).  The alternating 
wash procedure was repeated 5 times.  Finally, the surfaces were rinsed copiously with AFM 
buffer and loaded into the AFM. 
    In addition to the protein immobilization protocol, significant modifications were made to 
the data collection methods.  Force curves were collected in a 32 × 32 array over a 5 µm scan 
area using custom software written by Dr. Chad Ray, instead of 1000 curves at a single 
location.  At least 3 scan areas were examined per substrate with a 5 nm trigger during force 
curve collection.  Additionally, the spring constant was determined at the start of each scan 
area using a 30 nm trigger instead of the 3 nm trigger used in strategy 1.  The average spring 
constant value was used in the force calculations and data analyses.           
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    3.2.8 Custom Analysis Software.  The force versus distance curves collected via both 
strategies were analyzed using custom software written by Dr. Russell Taylor, Department of 
Computer Science at the University of North Carolina at Chapel Hill.  The program first 
converted cantilever deflection (raw data) versus tip-substrate separation distance to force 
versus separation distance curves using the average spring constant measured for the 
cantilever.  Interactions (events) were identified as changes in force exceeding a user-defined 
threshold, typically 20 pN.  Only the forces corresponding to events that occurred between 20 
and 500 nm from the surface were used to generate histograms.  For force curves collected 
via strategy 1, the histograms were generated by plotting the force of each event in 20 pN 
bins.  For force curves collected via strategy 2, the number of events in each bin was divided 
by the total number of events to generate histograms showing probability versus force in 20 
pN bins.  
 
3.3 Results and Discussion 
    3.3.1 Data Analysis.  The software written by Dr. Taylor calculated the rupture force and 
distance from the surface for each event in the force versus distance curves.  Two filters were 
applied to the data based on observations made by Dr. Ryan Fuierer and Dr. Oleg Gorkun.  
First, the observed baseline noise in the force curves was typically ~5 pN, therefore 20 pN 
was selected as the force threshold.  An additional filter based on the dimensions of 
fibrinogen was applied to the data to further ensure only specific fibrin-fibrin interactions 
were included in the analyses.  Only events occurring between 20 and 500 nm from the 
substrate were included in the histograms.   
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    Figure 3.2 shows a representative force versus distance curve containing several 
interactions (events) corresponding to bond ruptures between the desAB-NDSK on the tip 
and fibrinogen on the substrate.  A schematic of the desAB-NDSK interaction with 
fibrinogen is shown in Figure 3.1D.  While most of the force versus distance curves in a data 
set did not contain any interactions, the majority of the curves with interactions contained 
more than one event that satisfied the magnitude and distance criteria (Fig 3.2, *).  The 
appearance of multiple interactions rupturing in a single force versus distance curve presents 
numerous challenges to the identification of the specific bonds responsible.  Furthermore, 
multiple interactions occurring at different magnitudes such as those observed in this system 
led to multiple force populations in the resulting histograms.  A common cause of multiple 
events has previously been attributed to the formation of a single bond (e.g., an “A-a” knob-
hole interaction) between multiple pairs of interacting molecules on the tip and the substrate.  
Alternatively, multiple events could represent the formation of multiple bonds (e.g., “A-a” 
and “B-b” knob-hole interactions or αC-Bβ chain interactions) occurring between a single 
interacting pair of molecules containing multiple interaction sites.  At the advice of Dr. Boris 
Akhremitichev and Dr. Chad Ray at Duke University, several modifications were made to the 
protein immobilization method and data collection protocols to minimize the potential for 
multiple interacting pairs of molecules.  A detailed discussion of the changes implemented 
and the rationale is discussed below.  
 
    3.3.2 Comparison of Protein Immobilization Strategy 1 and 2.  Due to the complications of 
multiple interactions occurring within a single force versus distance curve, the majority of the 
modifications in protein immobilization were designed to reduce the possibility of protein  
 63
 
  
 
 
Figure 3.2  Representative force versus distance curve illustrating the observed signal as the 
desAB-NDSK modified AFM tip approaches (red) and retracts (blue) from the fibrinogen-
modified substrate. The events denoted by the asterisks illustrate the events that exceeded the 
20 pN force threshold and occurred between 20 and 500 nm from the surface; the user-
defined criteria for an event.   
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aggregates or clusters on the surface.  For example, decreasing the protein concentrations and 
co-immobilizing fibrinogen, D fragment or DD fragment with BSA ensured the active protein 
molecules were distributed far enough apart to prevent a single protein on the tip from 
interacting with two adjacent molecules on the surface.   Stringent washing protocols 
alternating between high salt and low pH were also designed to promote electrostatic 
repulsion between the proteins on the surface and dislodge any non-covalently attached 
fibrinogen, D fragment or DD fragment to reduce aggregates at the surface.   
    The changes in force curve collection and spring constant determination were designed to 
more accurately determine the spring constant and better sample the proteins on the substrate.  
The increase in the trigger to 30 nm during spring constant determination caused the 
cantilever to undergo a more significant deflection, generating a wider linear deflection 
region used during curve fitting.  The wider linear deflection range resulted in a more reliably 
measured spring constant.  Additionally, taking force curves in a 32 × 32 array over a 5 µm 
scan area provided a more accurate assessment of the interactions between different 
molecules on the substrate and the molecules on the tip, rather than interrogating a small 
population of molecules repeatedly as in Strategy 1.  The force curve collection in Strategy 1 
only examined 3 locations per substrate, whereas Strategy 2 examined 3072 locations per 
substrate.   
    The reproducibility of force curves acquired via Strategy 2 was significantly improved 
between 5 µm scans within a single surface, surface to surface, and day to day.  Figure 3.3 
shows histograms generated from the interactions between desAB-NDSK and fibrinogen 
using both strategies.  Despite the reproducibility improvements, the resulting histogram was  
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Figure 3.3  Histograms of the observed interactions between covalently immobilized desAB-
NDSK on the AFM tip and fibrinogen on the substrate generated via the two Strategies.   
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nearly identical for both strategies, suggesting the multiple interactions were not the result of 
protein aggregates or the immobilization methods.  Thus, it was concluded that the multiple 
interactions were more likely the result of complex, specific interactions between desAB-
NDSK and fibrinogen.  To elucidate which of the specific fibrin-fibrin interactions were 
contributing to the complex force curves, Strategy 2 was exclusively in subsequent studies 
with fibrinogen and its fragments.   
 
    3.3.3 Comparison of desA-NDSK and desAB-NDSK: Strategy 2.  To determine if the 
multiple peaks in the force curves represented rupture events between “A-a” and “B-b” 
interactions, the forces between desA-NDSK on the AFM tip and fibrinogen on the substrate 
were examined.  Since desA-NDSK contained only “A” active knobs, no “B-b” interactions 
were possible between desA-NDSK and fibrinogen.  Figure 3.4 illustrates representative 
histograms comparing the interactions of either desAB-NDSK or desA-NDSK on the AFM 
tip and fibrinogen on both substrates.  No differences were observed in the magnitude and 
appearance of events when both “A-a” and “B-b” interactions were possible compared to 
only “A-a” interactions, suggesting “B-b” knob-hole interactions did not contribute to the 
interactions observed between desAB-NDSK and fibrinogen.   
   
    3.3.4 Comparison of fibrinogen, D and DD fragment: Strategy 2.  Since fibrinogen is a 
large, complex molecule with many potential sites for specific interactions, examining the 
interactions with fragments of fibrinogen may provide more detail as to the specific region of  
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Figure 3.4  Histograms of the observed interactions between covalently immobilized desAB-
NDSK (top) and desA-NDSK (bottom) on the AFM tip and fibrinogen on the substrates 
generated via Strategy 2.   
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the protein responsible for the multiple interactions.  To elucidate whether the surface-bound 
fibrinogen’s coiled-coils or E region were participating in the interaction between desAB- 
NDSK and fibrinogen, experiments were conducted with the D fragment of fibrinogen 
instead of the full-length molecule (data not shown).  Yet again, no differences between 
desAB-NDSK interacting with fibrinogen compared to D fragment were observed.   
    To model “A-a” interactions occurring within protofibrils during fibrin formation, the 
interaction between desAB-NDSK and DD fragment were examined.  Protofibrils are 
double-stranded, half-staggered polymers held together by interactions between the E regions 
(similar to desAB-NDSK) of one strand and the two D regions of adjacent molecules in the 
opposite strand during clotting (Fig. 1.4).  The DD fragment is generated from a fully-
formed, covalently cross-linked clot and represents the interface of two adjacent molecules 
within a protofibril.  Since desAB-NDSK contains two “A” knobs per fragment, it is possible 
that an “A-a” bond could form between desAB-NDSK and each of the D regions contained 
in the DD fragment.  To determine how the establishment of two parallel “A-a” interactions 
would manifest in the histograms generated by Strategy 2, the interaction between desAB-
NDSK and DD fragment was examined.  Figure 3.5 is a representative histogram of the 
interactions between desAB-NDSK and DD fragment.  The observed interactions between 
desAB-NDSK and DD fragment did not contain two clearly pronounced populations of 
forces as was observed between desAB-NDSK and fibrinogen or D fragment.  Instead, a 
broad distribution of forces was observed.  Of note, forces significantly greater than 200 pN 
were not observed, suggesting the observed forces did not represent the rupture of two 
parallel “A-a” interactions.  The implications of the differences observed between DD  
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Figure 3.5  Histogram of the observed interactions between covalently immobilized desAB-
NDSK on the AFM tip and DD fragment. 
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fragment and D fragment or fibrinogen were not realized until further along in the 
progression of this project and is described at the end of this chapter. 
 
   3.3.5 Specificity of fibrin(ogen)-fibrin interactions: Strategy 2.  Since protein surfaces 
contain many charged and hydrophobic residues, the potential for non-specific interactions 
between any two proteins that come into contact with one another exists.  As such, great care 
must be taken during AFM force measurements to both minimize non-specific interactions 
and to ensure observed events are specific to the biochemical phenomenon of interest.  The 
AFM buffer developed by Dr. Gorkun containing 2 mg/mL BSA and 0.1% Triton X-100 
essentially eliminated non-specific interactions between fibrinogen and its fragments in the 
force range of the specific interactions (> 50 pN).  Nevertheless, a population of low 
magnitude forces (< 50 pN) was still frequently observed (Fig. 3.6 B,C).  Figure 3.6 
illustrates the interactions observed in the absence of active knobs (NDSK immobilized on 
the tip, fibrinogen on the substrate) and holes (desAB-NDSK on the tip and BSA on the 
substrate).  The use of an “A-a” inhibitor, Gly-Pro-Arg-Pro-amide, quenched the observed 
interactions between desAB-NDSK and fibrinogen (Fig. 3.6), indicating the rupture events 
occurring > 50 pN were the result of specific fibrin-fibrin interactions. 
    To further illustrate the specificity of the observed interactions, fibrinogen was covalently 
immobilized to both the tip and substrate allowing the examination of fibrinogen-fibrinogen 
interactions (Fig. 3.7A).  Next, the fibrinogen on the substrate was activated by thrombin to 
expose “A” and “B” knobs and the fibrinogen-fibrin interactions were examined.  Hirudin 
was used to inhibit thrombin and prevent premature activation of the remaining fibrinogen 
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Figure 3.6  Histograms of the observed non-specific interactions between A. NDSK and 
fibrinogen, B. desAB-NDSK and BSA, and C. desAB-NDSK and fibrinogen in the presence 
of 2 mM Gly-Pro-Arg-Pro-amide, a specific “A-a” interaction inhibitor.   
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Figure 3.7  Histograms of the observed interactions between A. fibrinogen on both surfaces, 
B. fibrin on the substrate and fibrinogen on the tip, and C. fibrin on both surfaces. 
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surface.  Finally, the fibrinogen on the tip was activated by thrombin to examine fibrin-fibrin 
interactions (Fig. 3.7C).  As shown in Figure 3.7A, predominately events of low force (< 50 
pN) were observed between fibrinogen and itself.  Upon converting fibrinogen to fibrin, 
specific forces appeared and increased in probability as both surfaces were activated (Fig. 
3.7B+C), suggesting the interactions were dependent upon the exposure of active knobs.   
 
3.4 Conclusions   
    The interaction between fibrin(ogen)-fibrin was more complex than anticipated based on 
results from previous laser tweezers studies (1).  To elucidate whether the multiple 
interactions observed were the result of a single interaction between multiple pairs of 
molecules (i.e. one “A-a bond between two fibrin-fibrinogen pairs) or multiple interactions 
between a single pair of molecules (i.e. one “A-a” and “B-b” bond between a single fibrin-
fibrinogen pair), modifications were made to both the sample preparation and data collection 
methods.  Since decreasing the amount of protein immobilized on the AFM surfaces only 
decreased the overall number of interactions and not their complexity, it was unlikely that a 
single interaction was occurring between multiple molecular pairs.  The multiple events 
observed in the force curves were likely the result of a complex series of interactions 
between a single molecule on the AFM tip and a single molecule on the substrate.  Several 
studies were completed to investigate potential sites of interactions such as “A-a” and “B-b” 
knob-hole interactions or αC-Bβ chain interactions.   
    DesA-NDSK and desAB-NDSK interacted similarly with fibrinogen and D fragment, 
suggesting “B-b” and αC-Bβ chain interactions were not participating in the interaction 
between desAB-NDSK and fibrinogen.  Of note, the interactions between desAB-NDSK and 
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DD fragment were different than desAB-NDSK and fibrinogen, but the exact nature of the 
difference was indiscernible by the software generously written by Dr. Taylor.  As a result of 
the major advances in protein immobilization and data collection, it became clear that the 
data analysis method was insufficient for examining the complex rupture patterns 
consistently observed between fibrin(ogen) and fibrin.  To assist with data analysis, a formal 
collaboration with Dr. Boris Akhremitichev was established.  Dr. Akhremetichev provided 
the Schoenfisch lab with custom MatLab v. 7.1 (MathWorks, Natick, MA) software designed 
to analyze complex ruptures more thoroughly (13).  The new analysis method coupled with 
several additional experiments enabled an in-depth examination of fibrin-fibrin interactions.  
The final result was a complex and fascinating study elucidating the nature of the intricate 
interactions observed between desAB-NDSK and fibrinogen as discussed next.   
     
3.5 Evolution of the Project 
    The majority of the work described in this chapter detailed the protein immobilization and 
data collection method development used to study fibrin-fibrin interactions by AFM.  
However, major collaborative advancements in data analysis subsequent to my independent 
contributions to this project, especially the custom software generously provided by Dr. 
Akhremitichev and analysis methods by Laurel Averett, enabled a thorough re-examination 
of the data presented in this chapter.  Upon the re-examination of the data and several 
additional experiments by Laurel, a characteristic pattern of forces related to the rupture of 
the “A-a” knob-hole interaction emerged.  Careful control experiments ruled out all known 
fibrin-fibrin interactions as the source of the complex characteristic pattern and the “A-a” 
bond was identified as the sole tether between desAB-NDSK on the tip and fibrinogen on the  
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Figure 3.8  Representative force versus separation curve showing the prevalent pattern of the 
rupture of interactions between desAB-NDSK (tip) and fibrinogen (substrate). Curves with 
any combination of the 4 events shown here were identified as the characteristic pattern of 
rupture. All characteristic curves included the doublet of events above 200 pN (event 2 & 3). 
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substrate.  The characteristic pattern of forces shown in Figure 3.8 illustrates the “signature” 
4-event rupture pattern observed between desAB-NDSK and fibrinogen.  The histogram 
resulting from the analysis of all events in the characteristic pattern is represented in Figure 
3.9.  Re-examination of the DD fragment data indicated the complexity of the characteristic 
pattern was due to structural changes within the D region of fibrinogen upon the rupture of 
the “A-a” bond.  Since the DD fragment has a covalent cross-link and a large interfacial 
region between the two D fragments in the dimer (Fig. 3.1), the structure of this fragment is 
substantively more rigid than that of D fragment or fibrinogen’s D region alone and 
deformations did not readily occur with this fragment (14).       
    In summary, this project was highly collaborative in nature and relied on the diverse 
expertise of several researchers with backgrounds in biochemistry, analytical chemistry, 
biophysics and physics.  It represents the first comprehensive study of the complexity of the 
“A-a” knob-hole interaction measured by AFM.   
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Figure 3.9  Distribution of forces observed between desAB-NDSK immobilized on the AFM 
tip and fibrinogen immobilized on the substrate. Bin size = 20 pN. 
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CHAPTER 4 
 
INFLUENCE OF GLUTATHIONE AND ITS DERIVATIVES ON FIBRINOGEN 
POLYMERIZATION 
 
 
4.1 Introduction 
    The complex relationship between glutathione species (GSX) found in the blood has 
been used to diagnose and monitor a number of disease states (1-4).  For example, increased 
glutathione (GSH) found in the lungs have been associated with cystic fibrosis, chronic 
obstructive airway disease, and asthma (5).  Conversely, the nitrosated analogue, S-
nitrosoglutathione (GSNO), has been used as a treatment for a number of cardiovascular 
disorders due to its anti-platelet (6-11) and vasodilatory effects (12-15).  As shown in Figure 
4.1, endogenously GSH is converted to GSNO through nitrosative species (N2O3) and other 
redox mechanisms involving transition metal centers (16).  In plasma, GSNO and other 
nitrosothiols react readily with protein thiols (e.g., free cysteine residues of serum albumin) 
to form stable protein-SNO complexes that serve as the ultimate sink for circulating NO (17, 
18).  The transfer of NO from low molecular weight thiols to proteins occurs via 
transnitrosation (direct transfer of NO from one thiol to another).  Transnitrosation is 
responsible for much NO transport in vivo resulting in a dynamic relationship between the 
high concentrations of GSH (500 µM) and the transient RSNO species (2 µM) in blood 
(Figure 4.1). Moreover, GSH can directly decompose nitrosothiol donors to form disulfides 
(e.g., GSSG) and multiple NOx species (19, 20).  
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Figure 4.1.  Schematic of the interconversion between GSH, GSSG and GSNO species. 
 
 
 
 
 
 
S-nitrosoglutathione (GSNO)Glutathione (GSH)
Oxidized glutathione disulfide
(GSSG)
N2O3 NO2- + H2O
NOx
Glutathione
reductase
RSNO
RSH
 82
    In a number of cases transnitrosation reactions of GSNO have been shown to result in S-
thiolation, forming mixed disulfides between proteins and glutathione (21).  The most 
significant example is thiolation of protein disulfide isomerase (PDI) by GSNO on the 
surface of platelets (22-24).  The NO released from glutathionylation of PDI diffuses across 
the plasma membrane and inhibits platelet activation via a guanylyl-cyclase dependent 
mechanism (6).  The mixed disulfide also plays a role in inhibiting platelet aggregation by 
interfering with the enzymatic function of PDI (22-24). Due to GSNO’s ability to mitigate 
platelet adhesion and aggregation, a number of animal and clinical studies have been 
conducted using GSNO and other nitrosothiols as novel anti-thrombotic agents (8-11).  Since 
activated platelets initiate the coagulation cascade, platelets have been an excellent target for 
RSNO intervention.  However, little emphasis has been placed on the effects of nitrosothiols 
and their decomposition products on subsequent aspects of thrombosis, specifically 
fibrinogen and fibrin formation.   
    Fibrinogen, a 340 kDa plasma protein, is composed of two copies each of three 
polypeptide chains, Aα, Bβ and γ (Fig. 1.1) (25).  Fibrinogen polymerizes upon activation by 
the enzyme thrombin to form a fibrin clot.  In vivo, fibrin serves as the structural scaffolding 
of the blood clot by stabilizing the initial platelet plug and localizing important wound 
healing and inflammation factors to the site of injury.  The transformation of fibrinogen to 
fibrin occurs in a multi-step process (Fig 1.4).  Thrombin cleaves fibrinopeptide A (FpA) 
from the N-terminus of fibrinogen’s Aα chains, exposing a new amino acid sequence (the 
“A” knob) and generating fibrin monomer (25).  The “A” knobs interact with holes “a” in 
other fibrin molecules to form double-stranded, half-staggard protofibrils.  Thrombin also 
cleaves fibrinopeptide B (FpB) from the N-termini of the Bβ chains, exposing the “B” knobs 
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that interact with holes “b” to form “B-b” interactions.  Upon removal of FpB, protofibrils 
lengthen, branch and laterally aggregate to form fibers.  Protofibril lateral aggregation is 
thought to be mediated predominantly by “B-b” interactions and intermolecular αC-αC 
interactions between the C-termini of the Aα chains (26, 27).  
      Mutus and co-workers examined the effects of GSNO on the initial rates of fibrin 
formation and found 4.0 ± 1.0 µM GSNO was sufficient to inhibit the initial rate by 50% 
(28).  GSNO-dependent structural changes in fibrinogen were studied using circular 
dichroism and tryptophan fluorescence spectroscopy.  The authors concluded that the 
observed inhibition was due to conformational changes in the C-terminal region of 
fibrinogen’s α chain induced by GSNO binding.  In this chapter, the role of the reduced, 
oxidized and nitrosated derivatives of glutathione on the entire process of fibrin formation 
are examined with the goal to expand the previous work beyond the exploration of initial 
rates of fibrin formation.  Lag time, Vmax, and final optical densities (OD) were examined for 
fibrinogen solutions treated with each of the GSX species and compared to normal.  Studies 
were also conducted to examine the rates of fibrinopeptide cleavage and the polymerization 
of a variant fibrinogen missing the αC domains to elucidate the mechanistic effects of 
nitrosothiols on fibrin formation.    
 
4.2 Experimental Methods 
    4.2.1 Materials.  Reagents were of analytical grade and purchased from Sigma (St. Louis, 
MO) unless noted otherwise. Human plasma fibrinogen (FIB 1) and α-thrombin (HT 
2970PA) were purchased from Enzyme Research Laboratories (Southbend, IN).  Fibrinogen 
was stored at -80 °C, thawed at 37 °C for 10 min and maintained at ambient temperature. The 
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buffer for all experiments was 20 mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.4 (HBSC).  
Protein concentration was determined using an extinction coefficient of 1.51 or 1.6 at 280 nm 
for a 1 mg/mL solution of normal fibrinogen and Aα251 fibrinogen, respectively (29).  
Recombinant normal and Aα251 fibrinogen were prepared as described previously (29, 30).  
Thrombin aliquots were freshly thawed, diluted to 10 U/mL and stored on ice.  Immediately 
prior to experiments, thrombin was diluted to 0.1 U/mL.  Reduced and oxidized glutathione 
solutions, GSH and GSSG, respectively, were dissolved in HBSC and stored on ice.     
 
    4.2.2 Synthesis of S-nitroso-glutathione (GSNO).  GSNO was synthesized according to a 
previously reported procedure (31).  Briefly, 100 mg of GSH were dissolved in 10 mL of 2 
M HCl at 0 °C and treated with a 2:1 molar excess of NaNO2.  After stirring for 30 min in the 
dark, 25 mL of acetone were added to the red solution and stirred for an additional 10 min on 
ice.  The pink GSNO precipitate was recovered via filtration, washed with cold water (2 x 10 
mL) and cold ether (2 x10 mL), dried under vacuum and stored at -20 ºC in the dark.  To 
minimize thermal decomposition, GSNO was kept on ice in the dark and diluted immediately 
prior to use for each experiment.  
  
    4.2.3 Fibrinogen Polymerization Assays.  Experiments were performed in triplicate using 
medium-binding 96-well microtiter plates.  Fibrinogen (100 µl) and either GSH, GSNO or 
GSSG (100 µL) was added to each well and incubated at 37 ºC for 10 min.  Next, thrombin 
(100 µl) was simultaneously added to each well to initiate fibrinogen polymerization.  
Changes in optical density (OD) were monitored at 405 nm using a SpectraMax plate reader.  
Final concentrations after all dilutions varied from 2-0.07 mg/mL (6-0.2 µM) fibrinogen and 
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500-0.03 µM GSH, GSSG or GSNO.  A final thrombin concentration of 0.03 U/mL (0.3 nM) 
was used for all polymerizations.     
 
    4.2.4 Analysis of Polymerization Results.  The maximum velocity of polymerization (Vmax) 
was determined as the steepest part of the polymerization curve by finding the maximum 
value of the 1st derivative.  Lag time was measured as the time of initial increase in optical 
density (OD) and the final OD was the turbidity value at the plateau in the polymerization 
curve.  A p value of ≤ 0.05 was considered significant according to unpaired t-tests.     
   
    4.2.5 Fibrinopeptide Release.  To initiate fibrinopeptide release, thrombin (10 µL of 1 
U/mL) was added to fibrinogen (2 mL of 0.1 mg/mL), mixed by inversion and pipetted into 
240 µL aliquots.  All protein manipulations were completed within 1 min after thrombin 
addition.  The reaction was quenched by placing each tube in boiling water for 15 min at 2, 5, 
10, 20, 40, 80 or 120 min after thrombin addition.  The boiled samples were stored on ice for 
the duration of the experiment.  Fibrinogen (240 µL) not treated with thrombin and 
fibrinogen (240 µL) treated for 60 min with an excess of thrombin (1 µL of 2360 U/mL) 
served as controls for no fibrinopeptide release and complete fibrinopeptide release, 
respectively.  Samples were spun for 10 min and the supernatant containing fibrinopeptides 
was stored at -80 ºC before detection by reverse-phase HPLC monitored at 210 nm as 
previously described (32).  The percent of FpA and FpB released was calculated relative to 
the amount of FpA or FpB detected after excess thrombin treatment.  The rates of FpA and 
FpB release were determined using kinetic equations described previously (33).        
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4.3 Results and Discussion 
    4.3.1 GSX Influence on Polymerization.  The dose-dependent effects of GSNO were 
evaluated over the entire process of fibrinogen (0.07 mg/mL) polymerization.    Similar to 
results by Mutus and co-workers, inhibition of fibrin formation was observed (maximum 
inhibition at 500 µM, Fig. 4.2).  The effects of reduced glutathione (GSH), the physiological 
precursor to GSNO, on fibrin formation were also investigated.  Unlike previously reported, 
the influence of GSH on fibrin formation was the same as GSNO.  Similar behavior was 
observed for the exogenous RSNO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP), the 
free thiol N-acetyl-DL-penicillamine (NAP), and the simplified derivative N-acetyl-DL-
cysteine, suggesting a clear relationship between the presence of reactive thiols and the 
inhibition of fibrin formation (data not shown).  The presence of N-acetyl-DL-serine 
(containing an alcohol moiety instead of a thiol) showed no effect on fibrin formation up to 
600 µM, analogous to the effects of carboxymethylated GSH (containing a protected, 
unreactive thiol moiety) reported by Akhter et al.. 
    Due to the abundance of GSH in plasma, the therapeutic utility of GSNO and the role of 
GSSG as a predicative marker for oxidative stress, the mechanistic effects of these species on 
fibrin formation were explored.  The representative polymerization curves for normal 
fibrinogen and in the presence of 500 µM GSNO are shown in Figure 4.2.  Relative to 
normal polymerization, glutathione and related derivatives delayed the fibrin formation, as 
evidenced by a reduced rise in turbidity and lower the final optical density (Fig. 4.2).  Based 
on methods described previously, three parameters related to critical aspects of fibrin 
formation were obtained from the polymerization curves (34).   The lag time, representative 
of the rate of protofibril formation (Fig. 4.2A), was measured when an increase in turbidity  
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Figure 4.2  Turbidity curves monitored spectrophotometrically at 405 nm comparing the 
polymerization of 0.07 mg/mL fibrinogen and 0.03 U/mL thrombin with and without GSNO.  
The three phases of the polymerization curves are as follows: A. Lag time is the time at when 
an increase in optical density was observed, B. region of the polymerization curve 
corresponding to the lateral aggregation of protofibrils, C. Final optical density of the 
turbidity curves (proportional to fibrin fiber diameter).     
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was first detected.  Factors that influence the lag time are the rate of FpA release and the 
ability of the activated fibrin monomers to interact with one another (34).  In the subsequent 
phase of polymerization, the protofibrils laterally aggregate to form fibers, leading to an 
increase in optical density in the polymerization curve (Fig. 4.2B).  Both FpB release 
(leading to “B-b” interactions) and αC-αC intermolecular interactions have been shown to 
influence lateral aggregation of protofibrils (26, 35).  The maximum rate of lateral 
aggregation or Vmax appears at the steepest part of the polymerization curve.  The final 
optical density (Fig. 4.2C) is proportional to the average fibrin fiber diameter and may 
provide insight into the structure of the resulting clot (34).  In general, clots formed from 
thicker fibers are more permeable and susceptible to lysis compared to clots formed from 
thinner fibers (36).        
    Figure 4.3 summarizes the three parameters of fibrinogen polymerization in the presence 
of GSH, GSSG and GSNO relative to normal conditions.  For clarity the results are reported 
as percentages of normal.  The addition of GSH, GSSG and GSNO caused a ~20% increase 
in lag time compared to normal; Vmax was reduced.  Compared to GSNO, the inhibition of 
Vmax was less for GSH or GSSG, but this difference was not significant according to an 
unpaired t-test (p = 0.11 and p = 0.16, respectively).  The addition of GSH or GSSG led to a 
~30% reduction in turbidity, whereas only a ~20% reduction was observed with GSNO.  The 
small difference in GSNO’s influence on final OD was significant compared to GSH (p = 
0.05) but not significant compared to GSSG (p = 0.12).  As would be expected, the final 
optical densities of all the clots formed in the presence of glutathione and its derivatives were 
reduced compared to normal.    
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Figure 4.3  The maximum rate of lateral aggregation (Vmax), clotting onset time (lag time) 
and final clot turbidity (OD) calculated relative to normal fibrin polymerization obtained 
from the turbidity curves in Figure 4.2.  The values obtained for normal were defined as 
100% and are denoted by the dashed lines.    
 
0
20
40
60
80
100
120
140
%
 R
el
at
iv
e 
to
 N
or
m
al
0
20
40
60
80
100
120
140
 
%
 R
el
at
iv
e 
to
 N
or
m
al
0
20
40
60
80
100
120
140
 
%
 R
el
at
iv
e 
to
 N
or
m
al
Vmax
Lag time
Final OD
GSH GSNO GSSG
 90
    Based on the results obtained from the polymerization curves, GSH, GSNO and GSSG 
influence fibrin formation to the same extent, contradicting a previous report that found 
GSNO but not GSSG influenced the initial rates of fibrin formation (28).  The authors did not 
examine the effects of unmodified GSH on polymerization of fibrinogen.  Importantly, two 
major differences between the experiments presented in this chapter and those reported 
previously exist.  First, the polymerization assays described herein examined the entire 
polymerization process instead of the first 100 s.  Second, the concentrations of fibrinogen 
and thrombin used in this study were lower compared to those used in the previous work.  
The lower concentration of thrombin was chosen to slowly polymerize fibrinogen to allow 
observation of early phases of fibrin formation that are difficult to observe at higher thrombin 
concentrations.   
    Since the concentration of GSH in blood is higher than GSSG and GSNO, the remainder 
of this chapter is focused on an in-depth analysis of fibrin formation in the presence of GSH.  
The work presented herein expands the significance of GSX’s influence on fibrin formation 
and suggests a regulatory role of glutathione in blood on fibrin formation 
  
    4.3.2 Dose-Dependent Effect of GSH.  The concentration of GSH in blood has been shown 
to fluctuate in response to numerous disease states (4, 37-40).  For example, GSH levels 
increase in response to the oxidative stress induced by cigarette smoking (38, 39).  
Consequently, investigation of the concentration dependence of GSH’s influence on fibrin 
polymerization may prove useful in understanding a broader impact of the up- or down-
regulation of this important antioxidant.   
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    The polymerization of 0.07 mg/mL fibrinogen was examined over a range of GSH 
concentrations (32 nM to 500 µM).  Figure 4.4 summarizes the dose-dependent effects of 
GSH on each of the polymerization parameters obtained from the polymerization curves 
(data not shown).  As expected, the greatest inhibition was observed at the largest GSH 
concentration (500 µM) where the lag time was prolonged by ~20% and the Vmax slowed by 
30%, indications that GSH impaired protofibril formation and lateral aggregation, 
respectively.  Of note, 100 and 500 µM GSH had the same effect on fibrin formation, 
suggesting maximal inhibition was achieved.  The three lowest concentrations of GSH (32, 
160 and 800 nM) did not significantly affect fibrin formation.  The dose-dependent influence 
of GSH on fibrinogen polymerization suggests changes in glutathione levels in response to 
oxidative stress or disease could also affect fibrin clot formation.   
 
    4.3.3 The Effect of GSH on Thrombin Activity.  Prolonged lag times and decreased rates of 
lateral aggregation were observed for the polymerization of 0.07 mg/mL fibrinogen at GSH 
concentrations above 800 nM and 500 µM GSH using fibrinogen concentrations less than 
0.25 mg/mL.  Previous studies have demonstrated that lag time is affected by the rate of FpA 
release (e.g., thrombin’s activity) and fibrin monomer assembly into protofibrils.  Similarly, 
the rate of lateral aggregation is influenced by FpB release and/or the assembly of protofibrils 
into branched, thicker fibers.  To determine if GSH impaired thrombin’s ability to activate 
fibrinogen thrombin activity was assayed directly.  The most common method used for 
assaying thrombin activity is based on a chromogenic substrate that undergoes a measurable 
absorption maximum shift upon cleavage by thrombin.  The intensity of the color change is 
proportional to the concentration of cleaved substrate and can be related to the activity of  
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Figure 4.4  The Vmax, lag time and final OD calculated relative to normal (no glutathione) 
fibrinogen polymerization of 0.07 mg/mL fibrinogen with 0.03 U/mL thrombin as a function 
of glutathione concentration.    The values obtained for normal were defined as 100% and are 
denoted by the dashed lines. 
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thrombin.  Unfortunately, the chromogenic assay only probes the function of thrombin’s 
active site and not the enzyme’s ability to bind fibrinogen and cleave fibrinopeptides.  As an 
alternative approach to the chromogenic assay, thrombin’s ability to cleave FpA and FpB 
from fibrinogen in the presence of GSH was measured directly via reverse-phase HPLC.  
Table 4.1 summarizes the kinetic constants for fibrinopeptide release with and without 500 
µM GSH.   
    No significant difference in the rate of FpA or FpB release from fibrinogen was observed 
in the presence of GSH compared to the absence, indicating a minimal GSH influence on 
thrombin.  Since fibrinopeptide release was normal under these conditions, the activation of 
fibrinogen to fibrin monomer and the release of FpB from protofibrils are assumed to be 
unaffected.  As such, fibrinogen activation is not influenced by GSH.  More likely, the 
effects of GSH on fibrinogen polymerization are the result of changes in the fibrinogen 
molecule that preclude its interaction with other fibrin molecules during fibrin formation.  
 
    4.3.4 Influence of Fibrinogen Concentration.  The normal rates of fibrinopeptide cleavage 
observed in the presence of GSH suggest that structural changes in fibrinogen are responsible 
for the inhibited rates of protofibril formation/aggregation.  To determine the influence of 
fibrinogen concentration, the concentration of fibrinogen was varied from 0.07 to 2 mg/mL 
in the presence of 500 µM GSH.  The results of the polymerization curves and parameters of 
polymerization relative to the normal polymerization of fibrinogen at each concentration are 
shown in Figure 4.5.  As the fibrinogen concentration increased from 0.07 mg/mL to 2.0 
mg/mL, an inversion of GSH’s effect on polymerization was observed at 0.25 mg/mL.  At 
fibrinogen concentrations below 0.25 mg/mL, GSH appeared to slow protofibril formation  
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Table 4.1.   Rate of thrombin-catalyzed FpA and FpB from normal and GSH-treated 
fibrinogen as detected by HPLC.   
 
 
 Rate of FpA Release (10-2 M-1s-1) Rate of FpB Release (10-2 M-1s-1) 
Experiment -GSH + GSH -GSH + GSH 
1 2.10 ± .16 1.56 ± .12 1.57 ± .79 1.35 ± .07 
2 1.66 ± .08 1.51 ± .05 1.23 ± .06 9.56 ± .04 
3 1.68 ± .06 2.10 ± .10 1.42 ± .05 1.55 ± .08 
Average 1.81 ± .25 1.72 ± .33 1.41 ± .17 1.29 ± .30 
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Figure 4.5  The Vmax, lag time and final OD calculated relative to normal (no glutathione) 
fibrinogen polymerization for each fibrinogen concentration with 0.03 U/mL thrombin and 
500 µM glutathione.  The values obtained for normal were defined as 100% and are denoted 
by the dashed lines. 
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and lateral aggregation as evidenced by prolonged lag times and lower Vmax values, 
respectively (Fig. 4.5).  The final OD’s of the resulting clots were also reduced with GSH 
compared to the normal clots at each concentration (Fig. 4.5).  At fibrinogen concentrations 
above 0.25 mg/mL, GSH had the opposite effect: Vmax was accelerated, the lag times were 
shorter, and the final ODs were larger compared normal clots at each concentration.  GSH’s 
influence on fibrin formation is thus dependent on fibrinogen concentration.    
  
        4.3.5 Mechanism of GSH’s Effect on Fibrin Formation.  Mutus and co-workers 
proposed several regions within the C-terminus of fibrinogen’s α chain (e.g., αC regions) as 
potential sites of interaction with GSNO (28).  Since no substantive differences were 
observed between the effects of GSNO, GSH and GSSG herein, the impairment of fibrin 
formation likely does not result from specific interactions between GSNO and aromatic 
residues within fibrinogen.   Rather, GSH and its derivatives act on fibrinogen in a thiol-
specific manner partially reducing disulfide bonds, leading to structural and functional 
alterations.  Indeed, fibrinogen contains 29 disulfide bonds, two of which are located in the 
highly solvent-accessible αC regions of the molecule (Fig. 1.2).  Due to their flexible 
structure and location (on the exterior of fibrinogen), the C-termini of the α chains are readily 
susceptible to reduction and/or degradation.  
    To determine if GSH alters fibrin formation via interaction with the αC regions, Aα251 
recombinant fibrinogen was employed.  Aα251 fibrinogen contains normal Bβ and γ chains, 
but only the first 251 residues of the Aα chain (29).  In other words, Aα251 lacks the αC 
regions.   
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 Aα251 polymerization as a function of GSH is shown in Figure 4.6.  As evidenced by 
identical turbidity curves, GSH had no measurable effect on the polymerization of Aα251.  
Previous work has demonstrated the importance of αC regions in polymerization (26, 41, 42).  
Fibrin formation for fibrinogen mutants lacking αC regions were characterized by prolonged 
lag times and reduced Vmax values, similar to the effects of exposure to GSH and its 
derivatives reported herein at low fibrinogen concentrations.  It is reasonable to conclude that 
reductions in the disulfide bridge in the αC regions induced by GSH, GSNO or GSSG may 
lead to changes in fibrin formation similar to those observed when functional αC regions are 
not present.       
 
4.4 Conclusions 
    The studies reported herein represent the first examination of the influence of reduced, 
oxidized and nitrosated glutathione on the entire process of fibrin formation.  Based on 
turbidity measurements, each of the glutathione derivatives inhibited fibrin formation to the 
same degree according to turbidity measurements.  While it is possible that GSH, GSSG, and 
GSNO interact via different mechanisms, a more likely explanation of the observed 
inhibition is that the glutathione species undergo thiolation reactions with fibrinogen.  
Studies using Aα251 recombinant fibrinogen indicate that the disulfides between Cys 442 
and 472 located in the exposed, solvent-accessible αC regions are critical to the normal 
polymerization of fibrinogen.  Understanding the interaction of glutathione and its 
derivatives with fibrinogen and their role in fibrin formation may provide a clearer picture of 
the physiological role of nitrosothiols and their decomposition products in vivo.   
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Figure 4.6  Turbidity curves monitored spectrophotometrically at 405 nm comparing the 
polymerization of 0.05 mg/mL Aα251 recombinant fibrinogen and 0.03 U/mL thrombin 
without gluathione (black trace) and 500 µM glutathione (grey trace).   
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CHAPTER 5 
 
SURFACE-DEPENDENT FIBRINOPEPTIDE A ACCESSIBILITY TO THROMBIN 
 
 
5.1 Introduction                                                                          
    Inadequate biocompatibility continues to limit the utility of blood-contacting medical 
devices such as stents and catheters (1).  One severe consequence of poor biocompatibility is 
surface induced thrombosis, or the undesirable formation of a blood clot at the blood/material 
interface.  Clots formed at the blood/material interface may occlude blood flow to/past the 
implant, impair proper function of the device, and/or dislodge from the surface and cause 
thrombotic embolism.  Much research has been devoted to understanding surface-induced 
thrombosis and its dependence on the surface properties of the underlying substrate (2, 3).  
However, few studies have examined the influence of surface properties on the mechanism of 
surface-induced thrombosis.              
    When an implanted material contacts blood, a series of pathologic responses involved in 
the coagulation cascade is triggered ultimately leading to thrombosis.  The initial event in the 
cascade is plasma protein adsorption, a process that mediates subsequent cellular interactions 
between cells and the surface of the material (4).  Of all plasma proteins, fibrinogen is of 
particular importance in thrombosis because of its dual role in modulating platelet adhesion 
and fibrin polymer formation (5).  Fibrinogen is a 340 kDa plasma protein composed of two 
copies each of three polypeptide chains (Aα, Bβ and γ) forming a trinodular structure (6-8).  
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As shown in Figure 5.1, the N-termini of all six chains are located in the center globular E 
region, while the C-termini of all six chains extend outward from the center forming two 
coiled-coil structures that terminate in a globular D region formed by the Bβ and γ chains 
(Fig. 5.1A).  Fibrinogen polymerization is initiated when the enzyme thrombin 
proteolytically cleaves the first 16 residues of the Aα chain, known as fibrinopeptide A 
(FpA).  After removal of FpA, fibrinogen is referred to as desA-fibrin monomer (Fig. 5.1B).  
The newly exposed N-terminus of the α chain forms an active site “A” that is able to bind to 
a corresponding polymerization hole “a” found in the D region of other fibrin monomers.  
The fibrin monomers spontaneously align via “A-a” interactions to form double-stranded, 
half-staggered protofibrils (Fig. 5.1C). Subsequently, thrombin cleaves the first 14 residues 
of the Bβ chain, fibrinopeptide B (FpB), exposing a “B” active site which binds to a 
corresponding polymerization hole “b” in the D region, allowing for “B-b” interactions.  
Ultimately, protofibrils lengthen and laterally aggregate forming highly branched, cable-like 
fibers that serve as the structural backbone of a clot.                      
    Previous studies have examined the influence of surface properties on fibrinogen 
adsorption and fibrin formation (9-13).  Evans-Nguyen et al. studied fibrinogen adsorption to 
self-assembled monolayers (SAMs) on gold presenting diverse terminal functional groups via 
surface plasmon resonance (SPR).  Similar amounts of fibrinogen were found to adsorb to 
hydrophobic and negatively-charged interfaces, yet the subsequent fibrin networks formed 
from the corresponding fibrinogen layers resulted in dramatically different clot structures (9).  
Fibrin formed at the hydrophobic surface was highly branched and contained a dense 
network while fibrin at the negatively-charged surface was sparse with few branch points. Sit   
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Figure adapted from (18). 
 
Figure 5.1  A. Structure illustrating fibrinogen’s D and E regions and FpA location in the 
center of the molecule and the color code for the three polypeptide chains.  B. Fibrin 
monomer formation upon thrombin cleavage of FpA. C. Spontaneous alignment of fibrin 
monomers forming characteristic half-staggard, double stranded protofibrils via “A:a” 
intermolecular interactions. 
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and Marchant observed similar trends when comparing fibrinogen polymerization at 
hydrophobic graphite to negatively-charged mica using atomic force microscopy (10).  Fibrin 
polymerization at surfaces appears to be highly dependent on surface charge and 
hydrophobicity. 
    To better understand the influence of surface properties on fibrin formation, Evans-
Nguyen et al. characterized the thrombin-catalyzed FpA cleavage from fibrinogen adsorbed 
to both hydrophobic and negatively-charged SAMs (12).  Unlike the fibrinogen adsorption 
characteristics, both the kinetics and quantities of FpA released were found to be 
significantly different, despite relatively similar amounts of fibrinogen adsorbed at the 
hydrophobic and negatively-charged SAMs.   Significantly less FpA was released at a slower 
rate from fibrinogen adsorbed to negatively charged (0.9 ± 0.2 pmol/cm2 and 0.071 ± 0.003 
min-1, respectively) versus hydrophobic SAMs (2.7 ± 0.4 pmol/cm2 and 0.17 ± 0.05 min-1, 
respectively) (12).  Of note, the mechanism explaining the observed differences in amount 
and rate of FpA cleavage has yet to be elucidated.   
    In this chapter, FpA accessibility studies for adsorbed fibrinogen were conducted to 
elucidate the mechanism by which surface properties influence thrombin-catalyzed 
fibrinopeptide release and fibrin formation.  The amount of accessible FpA on fibrinogen 
adsorbed to both hydrophobic and negatively-charged SAMs was quantified using polyclonal 
anti-FpA IgG binding in surface plasmon resonance (SPR) studies.  In addition, the 
susceptibility of FpA to thrombin-catalyzed fibrinopeptide cleavage from adsorbed 
fibrinogen was investigated to verify that available FpA was removed by thrombin.   
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5.2 Experimental Methods  
    5.2.1 Materials.  Dodecanethiol (HS-(CH2)11CH3) and 11-mercaptoundecanoic acid (HS-
(CH2)11COOH) were purchased from Sigma Scientific (St. Louis, MO) and used as received.  
Plasminogen-depleted human fibrinogen (FIB 1), human α-thrombin (HT 2970PA), sheep 
anti-human FpA purified IgG (SAFPA-IG 110) and non-immune sheep purified IgG (NIS-IG 
120) were purchased from Enzyme Research Laboratory (Southbend, IN).  HEPES-buffered 
saline with calcium (HBSC), [0.02 M HEPES, 0.15 M NaCl, and 1 mM CaCl2 (pH 7.4)] was 
used to both prepare protein solutions and as the buffer for all experiments.  The anti-FpA 
IgG was dialyzed against HBSC for 24 h prior to aliquot preparation and freezing.  
Fibrinogen and thrombin aliquots were stored at -80 °C while antibody aliquots were stored 
at -20 °C.  A fresh fibrinogen aliquot was thawed daily at 37 °C and kept at room 
temperature.  Fresh thrombin and antibody aliquots were thawed and kept on ice.  Water was 
purified using a Milli-Q A10 gradient UV system (Millipore Corp., Billerica, MA) to a final 
resistivity of 18.2 MΩ•cm and a total organic content of < 6 ppb.    
    
     5.2.2 Preparation of gold substrates.  Gold substrates were prepared according to the 
method previously described by Evans-Nguyen et al (11).  Briefly, glass microscope 
coverslips (Electron Microscopy Sciences, Washington, PA) were cleaned in piranha solution 
(1:3 v/v 30 % hydrogen peroxide: concentrated sulfuric acid) and rinsed thoroughly.  The 
coverslips were coated with a 3 nm chromium adhesion layer followed by a 45 nm gold 
layer.  Upon removal, the gold-coated coverslips were stored in absolute ethanol until used.  
Thiol solutions of methyl- and carboxylic acid-terminated self-assembled monolayers were 
generated by immersing the gold-coated substrates in dodecanethiol and 11-
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mercaptoundecanoic acid solution (2 mM in absolute ethanol), respectively, overnight 
immediately prior to use in experiments. 
    
     5.2.3 Surface plasmon resonance.  All SPR experiments were conducted using a BIAcore 
X instrument (Biacore, Inc., Uppsala, Sweden) and repeated in triplicate.  Gold-coated 
coverslips were removed from the thiol solutions and rinsed copiously with ethanol and 
Milli-Q water.  The sensorchips were dried under a gentle stream of nitrogen before 
placement into the SPR instrument.  The HBSC flow rate was adjusted to 10 µl/min and 
maintained through the instrument at all times.  After a stable baseline (<1 response unit/min) 
was achieved, 1 mg/mL fibrinogen was injected over the sensorchip surface for 600 s to 
allow fibrinogen adsorption.  The adsorbed fibrinogen layer was then washed with HBSC for 
300 s, and rinsed three times with buffer using Biacore’s software “wash” command over a 
second 300 s period prior to any additional injections.   
   
  5.2.4 FpA accessibility studies.  A 40 nM anti-FpA solution was introduced for 600 s over 
fibrinogen adsorbed to the hydrophobic and negatively-charged interfaces.   The relative 
amount of FpA available on fibrinogen at each surface was determined by monitoring the 
antibody association and dissociation profiles for 600 s each.    A competitive enzyme-linked 
immunosorbent assay (ELISA) was performed to determine the concentration of free FpA 
sufficient to block antibody binding to FpA on adsorbed fibrinogen (data not shown).  Based 
on the ELISA results, 240 nM free FpA was used to inhibit 40 nM anti-FpA and determine 
the non-specific antibody binding to fibrinogen at both surfaces. The antibody/inhibitor 
solution was incubated for 1 h and then introduced to the adsorbed fibrinogen layer.  Non-
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specific association and dissociation were monitored for 600 s each and subtracted from the 
association and dissociation curves obtained when 40 nM anti-FpA alone was injected over 
the adsorbed fibrinogen to yield specific anti-FpA binding responses.  The specific antibody 
association and dissociation profiles were also normalized with respect to the amount of 
fibrinogen adsorbed during each experiment by dividing each antibody binding profile by the 
net fibrinogen response (difference in response immediately prior to antibody injection and 
prior to fibrinogen injection.)   
    
     5.2.5 Fibrinopeptide A susceptibility to thrombin cleavage.  1 mg/mL fibrinogen was 
deposited on each surface for 600 s followed by 600 s of rinsing with HBSC.  Thrombin-
catalyzed fibrinopeptide cleavage was initiated by flowing 5 U/mL thrombin over fibrinogen 
adsorbed to both the hydrophobic and negatively-charged surfaces for 600 s.  To prevent 
thrombin carry-over, a 600 s injection of 40 U/mL hirudin, a thrombin inhibitor (14, 15), was 
performed prior to the antibody injection.  A 40 nM anti-FpA solution was then introduced 
over the thrombin-treated fibrinogen layers while monitoring antibody association and 
dissociation profiles.  Antibody signals were normalized to the amount of fibrinogen 
deposited at each surface in the same manner as described above.  After each experiment, the 
SPR flow cells were rinsed with 10 mg/mL pepsin (20 mM citrate buffer; pH 3, 300 s) 
followed by 0.5 %  (w/v) sodium dodecyl sulphate (SDS) solution (300 s) to remove residual 
thrombin and possible fibrin and to prevent blockage of the SPR flow cells.   The flow cells 
were rinsed several times with HBSC to remove remaining SDS prior to additional 
experiments.     
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Figure 5.2  A. Representative SPR sensorgram of response unit changes observed during (1) 
injection of fibrinogen, (2) injection of anti-FpA and (3) partial anti-FpA dissociation upon 
restoration of buffer flow for a hydrophobic surface.  B. 40 nM anti-FpA with and without 
240 nM free FpA binding to fibrinogen adsorbed to the hydrophobic SAM as determined by 
SPR.  The antibody binding curve was obtained by zeroing time and response axes at point 2 
in Figure 5.2A and normalizing for the amount of fibrinogen at each surface.  C. 40 nM anti-
FpA with and without 240 nM free FpA binding to fibrinogen adsorbed to the negatively 
charged SAM as determined by SPR.  The antibody binding curve was obtained by zeroing 
time and response axes at point 2 in Figure 5.2A and normalizing for the amount of 
fibrinogen at each surface.  D.  Specific anti-FpA binding to fibrinogen adsorbed to the 
hydrophobic and negatively charged surface.  Specific antibody binding was calculated as the 
difference between SPR signals measured for antibody and antibody inhibited with 240 nM 
FpA binding to fibrinogen at each surface.  Error bars depicted every 200 s in panels B-D 
represent the standard deviation of antibody binding responses obtained from three separate 
experiments. 
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5.3 Results 
    5.3.1 Fibrinopeptide A accessibility.   Fibrinopeptide A accessibility was measured as anti-
FpA binding to adsorbed fibrinogen using surface plasmon resonance.  A representative SPR 
sensorgram is shown in Figure 5.2A.  Upon addition of 1 mg/mL fibrinogen to the flow cell, 
rapid increase in SPR response was observed corresponding to fibrinogen adsorption to the 
surface (i.e., SAM-modified interface) (Fig. 5.2A, 1).  The amount of irreversibly adsorbed 
fibrinogen at the hydrophobic and negatively-charged surfaces (5531 ± 738 response units 
and 5255 ± 413 response units, respectively) was comparable 20 min after initial fibrinogen 
adsorption.  The fibrinogen adsorption signals observed for both the hydrophobic and 
negatively-charged surfaces correlated well with previous reports using similar conditions 
and instrumentation (11, 13). 
    An increase in instrument response was observed upon introduction of the antibody to the 
SPR flow cells (Fig. 5.2A, 2), indicating association of the antibody with accessible FpA.  
After the antibody injection was complete and buffer flow restored, partial dissociation of the 
antibody from the adsorbed fibrinogen was noted (Fig. 5.2A, 3) suggesting the antibody’s 
interaction with fibrinogen was partly reversible over the course of our experiments.  Due to 
the non-selective sensing principles of SPR, all antibody binding near the surface would elicit 
an instrument response, regardless of the interaction’s specificity.  Thus, the SPR response 
includes both specific and non-specific binding signals.   To correlate anti-FpA binding to 
FpA availability on fibrinogen at both surfaces, only the specific anti-FpA interaction with 
FpA on fibrinogen should be considered.  Non-specific anti-FpA binding to fibrinogen was 
consequently quantified for both surfaces using a competitive binding assay where 240 nM 
free FpA was present during the antibody injection.   
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    The antibody binding profiles normalized for fibrinogen adsorption at both surfaces are 
shown in Figure 5.2B-C.   Following anti-FpA injection, an increase in SPR response was 
observed indicating antibody association with fibrinogen at both surfaces (Figure 5.2B-C, 
upper curves).  Upon completion of the injection at 600 s, buffer flow resumed over the 
adsorbed fibrinogen for an additional 600 s and a decrease in SPR response indicating partial 
dissociation of bound antibody was observed.  In the case of anti-FpA in the presence of 
excess FpA (Fig. 5.2B-C, lower curves), a smaller increase in SPR response was observed 
upon injection of the inhibited antibody for both the hydrophobic and negatively charged 
surfaces.  The smaller but detectable binding responses observed for the inhibited antibody 
injections at both surfaces indicated that non-specific interactions contribute to the total 
antibody binding signal (Table 5.1).  Anti-FpA binding was greater at the hydrophobic 
surface compared to the negatively-charged surface (Fig. 5.2B-C) indicating less anti-FpA 
bound to fibrinogen at the negatively charged surface.  In contrast, there were fewer non-
specific interactions at the hydrophobic surface (relative to the negatively-charged surface) as 
indicated by the reduced binding of inhibited antibody.        
    Figure 5.2D illustrates the clear contrast between specific anti-FpA binding to fibrinogen 
at the hydrophobic and negatively-charged surfaces.  Indeed, a greater amount anti-FpA 
associated with fibrinogen adsorbed on a hydrophobic surface compared to a negatively-
charged surface.  Specific anti-FpA binding was 2.7 times higher to fibrinogen adsorbed on 
the hydrophobic surface compared to the negatively charged surface 20 min after the initial 
antibody injection, indicating greater FpA availability on the hydrophobic SAM (Table 5.1).       
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Table 5.1 Anti-FpA Binding to Immobilized Fibrinogen as measured via surface plasmon 
resonance 1200 s after anti-FpA injections, normalized as described in methods.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surface Anti-FpA alone Anti-FpA and FpA 
Anti-FpA after 
thrombin 
Specific anti-FpA 
binding 
Hydrophobic 43.2 ± 8.1 1.7 ± 0.8 2.0 ± 1.2 41.5 ± 8.1 
Negatively Charged 21.1 ± 5.6 5.6 ± 1.0 6.2 ± 2.4 15.4 ± 5.7 
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Figure 5.3  A. Representative SPR sensorgram of response unit changes observed during 
injection of (1) fibrinogen, (2) thrombin (3) hirudin, and (4) anti-FpA for the hydrophobic 
surface.  B. 40 nM anti-FpA binding to thrombin-treated fibrinogen.  The normalized 
antibody binding curve was obtained by zeroing time and response axes at point 4 in Figure 
5.3A and normalizing for the amount of fibrinogen deposited at point 1 in Figure 5.3A for the 
hydrophobic surface. 
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    5.3.2 Fibrinopeptide A susceptibility to thrombin cleavage.  To investigate thrombin’s 
ability to cleave available FpA on adsorbed fibrinogen, SPR was employed to measure anti-
FpA binding to fibrinogen after thrombin-catalyzed FpA cleavage.  As shown in Figure 5.3A, 
the initial increase in SPR response showed fibrinogen adsorption to the surface (Fig. 5.3A, 
1).  Upon injection of thrombin, a decrease in SPR response due to cleavage of 
fibrinopeptides A and B was observed.  The response correlated well with previously 
published SPR data for thrombin cleavage (12).  Hirudin was introduced to inhibit residual 
thrombin (14), and thebinding of anti-FpA assessed the remaining available FpA.  The SPR 
response was normalized to the amount of fibrinogen remaining on the surface just prior to 
anti-FpA injection and a representative binding curve is shown in Figure 5.3B.  The 
normalized SPR responses for anti-FpA bound to thrombin-treated fibrinogen 1200 s after 
antibody injection were 2.0 ± 1.2 and 6.2 ± 2.4 at the hydrophobic and negatively-charged 
surfaces, respectively.  Antibody binding after thrombin-catalyzed fibrinopeptide cleavage 
correlated well with the level of non-specific antibody interaction observed for each surface 
with anti-FpA in the presence of 240 nM FpA (Table 5.1).  This indicates that all available 
FpA was susceptible to thrombin cleavage, as expected.  Of note, a significantly higher level 
of non-specific interaction was observed at the negatively-charged (compared to the 
hydrophobic) surface under both conditions; i.e., thrombin exposure and inhibition with FpA 
(Table 5.1).  Our results indicate all FpA recognized by the antibody is cleaved by thrombin 
and only non-specific interactions contribute to the observed antibody binding signal after 
thrombin exposure.         
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5.4 Discussion 
    The accessibility and susceptibility of FpA to thrombin-catalyzed fibrinopeptide cleavage 
from adsorbed fibrinogen at hydrophobic and negatively-charged surfaces were evaluated.  
As determined by specific anti-FpA binding assays, roughly 2.7 times more FpA was 
available at hydrophobic versus negatively-charged interfaces (Table 5.1), indicating the 
amount of FpA available for thrombin cleavage is highly dependent on the properties of the 
underlying surface.  These results correlate well with studies by Evans-Nguyen et al. that 
reported three times more FpA is released from fibrinogen adsorbed to a hydrophobic surface 
relative to a negatively-charged surface (12).  Our findings provide the mechanistic basis 
(i.e., FpA availability) of surface-dependent FpA release reported previously (12).  
    The results also explain the reduced fibrin formation observed by Sit and Marchant at 
negatively-charged mica relative to hydrophobic graphite (10).  Sit and Marchant proposed 
several hypotheses for reduced fibrin formation at mica including altered fibrinogen 
conformation, electrostatic interferences and thrombin inactivity (10).  While adsorbed 
fibrinogen conformation and orientation has been shown to vary as a function of underlying 
surface properties (16, 17), the accessibility of polymerization sites such as FpA has not been 
previously evaluated.  The increased FpA availability at the hydrophobic SAM suggests 
fibrinogen exists in a favorable orientation more suitable for thrombin-catalyzed 
fibrinopeptide A cleavage.  However, available FpA was removed upon thrombin exposure 
to fibrinogen at both the hydrophobic and negatively-charged surfaces.  Therefore, all 
accessible FpA was equally susceptible to thrombin cleavage and thrombin activity was not 
influenced by the underlying surface chemistry.  Based on our data, reduced fibrin formation 
at the negatively-charged interface is the result of FpA availability.  Consequently, if FpA is 
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unavailable, thrombin is not able to expose the “A” active site (Fig. 4.1B) and fibrin 
formation will not occur.       
    Although previous studies have shown reduced FpA release and fibrin formation at 
negatively-charged surfaces, the explanation for these observations remained unclear (10, 
12).  Our findings provide key insight into the surface-dependent behavior of fibrin formation 
of adsorbed fibrinogen.  The results suggest negatively-charged surfaces may be useful in 
minimizing surface-induced thrombosis, and thus aid in the development of more 
biocompatible blood-contacting devices.     
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS OF THIS RESEARCH 
 
6.1 Summary 
    The work detailed in this dissertation combines the technologies of surface-based 
analytical methods and biochemistry to deepen the current understanding of the mechanism 
of fibrin formation in solution and at interfaces.  In Chapter 2, surface plasmon resonance 
was used to detect both “A-a” and “B-b” knob-hole interactions occurring between desAB-
NDSK and fibrinogen.  Equilibrium dissociation constants of 5.8 ± 1.1 and 3.7 ± 0.7 µM 
were measured for desA- and desAB-NDSK, respectively binding to adsorbed fibrinogen.  
Peptide inhibition studies showed desAB-NDSK binding to fibrinogen was reduced by both 
“A-a” and “B-b” interaction inhibitors, providing evidence that “B-b” interactions may occur 
alongside “A-a” interactions.  These experiments demonstrate “B-b” interactions may have a 
more substantive role in protofibril formation than previously thought.     
    In Chapter 3, protein immobilization and data collection strategies were optimized to 
develop an atomic force microscopy method to measure the mechanical properties of the 
bonds that rupture upon the dissociation of fibrin-fibrinogen interactions.  This method was 
used to investigate the complexity of the “A-a” knob-hole interaction and found molecular 
deformations occur within fibrinogen upon the forced rupture of the “A-a” bond.  In Chapter 
4, the effects of S-nitrosoglutathione and glutathione (oxidized and reduced) on the 
mechanism of fibrin formation were investigated using turbidity measurements.  GSNO, 
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GSH and GSSG each led to slower rates of protofibril assembly and lateral aggregation.  The 
final turbidities of clots formed in the presence of GSNO, GSH and GSSG were significantly 
reduced compared to normal.  While previous reports have examined the influence of GSNO 
on the initial rate of polymerization, this research represents the first examination of GSNO, 
GSH and GSSG on the entire fibrin formation process and a previously unreported role of 
GSH.  In Chapter 5, surface plasmon resonance studies were used to demonstrate that 
fibrinopeptide A was ~ 2.7 times more available for thrombin cleavage on fibrinogen 
adsorbed at a model hydrophobic surface compared to negatively charged surface, providing 
an explanation for reduced fibrin formation observed at negatively charged substrates.   
 
6.2 Future Directions of this Research 
    Despite a deeper understanding of the mechanism of fibrin formation in solution and at 
surfaces provided by this research, many unanswered questions remain.  The utility of 
surface-based analytical methods such as surface plasmon resonance (SPR) and atomic force 
microscopy (AFM) has been clearly established in the literature and this dissertation (1-8).  
However, the instrumental techniques (SPR and AFM) alone are insufficient at answering 
mechanistic questions regarding complex biological processes.  Combining the capabilities 
of surface-based analytical methods with relevant biological reagents (e.g., recombinant 
fibrinogens or cells) has the power to enable future researchers to probe critical aspects of 
fibrin formation and other important systems.   
 
    6.2.1 SPR investigation of role of “B-b” interactions in protofibril formation.  In Chapter 
2, “B-b” interactions were detected via selective “B-b” interaction inhibitors.  However, “B-
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b” interactions were only measured in conjunction with “A-a” interactions.  The individual 
contribution of “B-b” interactions to the binding affinity of desAB-NDSK for fibrinogen 
remains unclear.  To further investigate the role of “B-b” interactions in protofibril formation 
in the absence of “A-a” interactions, experiments with a recombinant fibrinogen having 
impaired holes “a” could prove very useful.  Specifically, γD364H fibrinogen containing 
non-functional holes “a” (9) could be adsorbed on the hydrophobic SAM.  The interactions 
of desAB-NDSK and desA-NDSK with the mutants would be assessed in the same manner 
as described in Chapter 2.  Since γD364H can not support “A-a” interactions, any binding of 
desAB-NDSK to this mutant would arise from “B-b” or “A-b” interactions.  DesA-NDSK 
could be used to determine the extent of “A-b” interactions since desA-NDSK only has “A” 
knobs available; “B-b” interactions are not possible with this fragment.  By comparing the 
binding of desAB-NDSK and desA-NDSK to γD364H, a measure of the affinity of “B-b” 
interactions independent of “A-a” interactions would be possible.  The direct measurement of 
the affinity of “B-b” interactions would provide a clearer picture of the role of “B-b” 
interactions in the early phases of polymerization (i.e., protofibril formation).     
 
    6.2.2 DesAB-NDSK and desA-NDSK interaction with DD fragment.  During fibrin 
formation, the molecules align end-to-end within a protofibril and one E region interacts with 
two D regions on the opposite strand of the protofibril (Fig. 1.4).  Therefore, both “A” knobs 
in fibrin’s E region interact each with holes “a” located in the D regions of two adjacent 
fibrin molecules (i.e., one desA- or desAB-NDSK binding to two D regions).   The SPR 
experiments described in this dissertation involved fibrinogen adsorbed to a surface and the 
interaction of one desA- or desAB-NDSK with one of the two D regions within fibrinogen.  
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To better model “A-a” and “B-b” knob-hole interactions occurring within a protofibril, SPR 
studies quantifying desAB-NDSK and desA-NDSK interactions with DD fragment would be 
useful.  The DD fragment contains two D regions “fixed” as they would be within a 
protofibril by FXIII, an enzyme that cross-links specific residues in fibrin (10).  By 
examining the interaction of desA- or desAB-NDSK with DD fragment, the synergistic effect 
on the affinity of multiple knob-hole interactions (e.g., two “A-a” or two “A-a” and “B-b” 
interactions) could be directly measured for the first time.  The measurement of the affinity 
of knob-hole interactions occurring between fibrin molecules as they exist in protofibrils 
would provide useful information in understanding the interactions responsible for protofibril 
formation and provide deeper understanding of the mechanism of the early steps in fibrin 
formation.   
 
    6.2.3 Effects of surface properties on desAB-NDSK binding to fibrinogen.  Previous 
studies have demonstrated impaired fibrin formation at negatively charged substrates 
compared to hydrophobic surfaces (11-13).  Evans-Nguyen et al. found thrombin cleaved ~ 3 
times more FpA from fibrinogen adsorbed at a hydrophobic surface compared to a negatively 
charged surface (12).  The work in Chapter 5 showed FpA is ~ 3 times more accessible to 
thrombin on fibrinogen adsorbed at the hydrophobic compared to the negatively charged 
surface, providing an explanation for Evans-Nguyen et al. results.  However, the influence of 
surface properties on subsequent phases of fibrin formation, such as fibrin (desAB-NDSK) 
binding to fibrinogen has not been fully studied.  The work detailed in Chapter 2 
characterized desA- and desAB-NDSK binding to fibrinogen adsorbed at a hydrophobic 
surface.  Investigating desA- and desAB-NDSK binding to fibrinogen adsorbed at model 
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hydrophilic, positively charged and negatively charged surfaces could provide crucial insight 
into additional mechanisms by which surface properties influence fibrin formation.  One 
study has previously examined the influence of surface properties on the binding of 
fibrinogen to adsorbed fibrin monomers (desAB-fibrin) (14). Only “A-a” with “B-b” 
interactions were examined since thrombin activation was used exclusively.  The influence of 
surface properties on “A-a” interactions alone in addition to “A-a” with “B-b” interactions 
were not examined.  Differences in thrombin’s ability to cleave fibrinopeptides from 
fibrinogen at different surfaces were not considered.  Evans-Nguyen reported that thrombin 
interactions with adsorbed fibrinogen were highly dependent on the underlying substrate 
(12).  The alternative approach described herein would avoid introducing surface-dependent 
differences in the adsorbed fibrin layers because the fibrin source would be soluble desA- or 
desAB-NDSK.  The interactions between soluble desA-or desAB-fibrin fragments and 
fibrinogen adsorbed at a hydrophilic, hydrophobic, positively and negatively charged 
surfaces would allow for comparison of “A-a” with “B-b” and “A-a” interactions alone as a 
function of surface properties.  Fully understanding the extent of the influence of surface 
properties on the mechanism of fibrin formation could be useful in developing materials to 
prevent or control surface-induced thrombosis. 
 
    6.2.4 Application of the AFM method to study fibrinogen-platelet interactions.  The 
development of a robust, reliable AFM method in combination with sophisticated data 
analyses for measuring the forces of rupture for fibrin-fibrin interactions enables future 
researchers to apply the same method, with minor modifications, to investigate numerous 
biological systems.  For example, the interaction between fibrin(ogen) and the platelet 
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integrin αIIbβ3, the protein responsible for the aggregation of platelets via fibrinogen bridging, 
could be studied using the methods developed in Chapter 3.  Previous work has examined the 
forces of interaction between fibrinogen and purified αIIbβ3 or αIIbβ3 bound to a synthetic 
membrane (15-17).  However, no AFM studies have examined the forces of interaction 
between fibrinogen and αIIbβ3 located within the platelet membrane due to complications 
associated with rupture data convoluted with molecular and/or cellular deformations.  The 
methods and data analyses developed herein to investigate complex fibrin-fibrin interactions 
may be capable of distinguishing specific interactions between fibrinogen and αIIbβ3 within 
the platelet membrane from those related to molecular or cellular deformations.  A 
monoclonal antibody specific to αIIbβ3 could be used to examine the molecular and cellular 
deformations that result from an applied force to the αIIbβ3 integrin, independent of specific 
fibrinogen-integrin interactions.  Unmodified AFM tips could be used to characterize the 
deformability of the platelets upon compression.   
    In addition to fundamentally characterizing the physical properties of the interactions 
between fibrinogen and αIIbβ3 within a platelet membrane, the AFM may allow the study of 
the distribution of αIIbβ3 integrins over the surface of the platelet.  Only activated platelets 
present the active form of the fibrinogen receptor (αIIbβ3) on their surface.  Since platelets 
(upon activation) can be up to 10 µm in diameter (much larger than the diameter of the AFM 
tip), the distribution of fibrinogen receptors on the platelet surface could be “mapped” by 
collecting an array of force versus separation distance curves across the surface of a single 
platelet.  Once the fibrinogen- αIIbβ3 rupture “signature” has been identified, the surface of the 
cell could be screened for specific interactions that could easily be distinguished from non-
specific fibrinogen-platelet interactions.  The cell could then be imaged with the AFM probe 
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or the AFM could be coupled to an inverted microscope, and the location/magnitude of the 
specific αIIbβ3 interactions with fibrinogen could be overlaid with the platelet image.  The 
distribution of αIIbβ3 over the platelet surface, as well as information regarding the strength 
and mechanical properties of the interaction between fibrinogen and αIIbβ3 could be obtained 
from a single experiment.  Since αIIbβ3 would be located in its natural environment (e.g., 
bound to the platelet membrane) the results may enable a deeper understanding of platelet-
fibrinogen interactions critical to thrombosis.  It would also be interesting to compare the 
distribution and function of αIIbβ3 activated via different methods of platelet stimulation (e.g., 
thrombin or other agonists) since the mechanism of activation could influence the 
distribution of αIIbβ3 on the platelet surface.  Previous studies have quantified fibrinogen 
binding to platelets (18), but information regarding the distribution of bound fibrinogen on 
the platelet surface has not been reported using AFM. 
    To investigate factors that may influence the interactions between fibrinogen and αIIbβ3, 
force measurements could be acquired as a function of NO-exposure via small molecule NO 
donors (e.g., S-nitrosothiols).  These studies are particularly interesting since NO has been 
shown to affect platelet aggregation (19-23).  The relationship between NO exposure the 
mechanical properties of the fibrinogen and αIIbβ3 interaction have not been reported.  
Investigation of the NO-dependent effects on the fibrinogen-αIIbβ3 interaction could provide 
unique information regarding the mechanism of reduced platelet aggregation due to NO 
exposure.   
 
    6.2.4 Application of the AFM method to study fibrinogen-bacteria interactions. Similar to 
fibrinogen-platelet interactions, fibrinogen-bacterium interactions could be investigated using 
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the method developed in Chapter 3.  Staphylococci have been shown to bind fibrinogen via 
several membrane-bound receptors (24, 25).  Yet, the distribution of the fibrinogen-specific 
receptors on the surface of the bacterial cell has not been thoroughly investigated.  The AFM 
method developed in Chapter 3 could be used to investigate both the intricacies of the 
fibrinogen-fibrinogen receptor interactions in their natural state (e.g., bound within the cell 
membrane) and the location of these interactions on the cell surface.  Although previous 
studies have examined the adhesion strength of bacterial cells to fibrinogen-coated surfaces 
or the interaction between fibrinogen and purified fibrinogen receptors (e.g., clumping factor 
A and fibronectin binding protein), the force of interaction between fibrinogen and the 
fibrinogen receptors on a living cell has not been reported.   
    Once the characteristic interaction between fibrinogen and the fibrinogen-specific 
receptors on the cell surface has been elucidated, numerous investigations relevant to 
biomedical infection could be completed.  For example, the interactions between fibrinogen 
and membrane proteins on the bacterial cell surface could be examined as a function of 
adhesion time or underlying substrate surface properties.  Investigating the distribution of 
fibrinogen receptors on bacterial cells adhered to a variety of biomaterials or nitric oxide 
(NO)-releasing films could provide key insight into the mechanism of implant-associated 
infections in vivo.  Numerous reports from the Schoenfisch lab have detailed the 
antimicrobial effects of NO and reduced adhesion of bacteria to NO-releasing surfaces (26-
31).  Additionally, the effects of NO on fibrinogen-mediated adhesion have been examined.  
Bacterial adhesion to fibrinogen-coated NO-release surfaces was reduced compared to 
control surfaces incapable of NO release (32).   
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    However, the mechanism by which NO reduces fibrinogen-mediated adhesion has not 
been examined.  The AFM method developed in Chapter 3 is well-suited to make significant 
strides in understanding NO’s effect on specific fibrinogen-fibrinogen receptor interactions.  
For example, fibrinogen could be covalently attached to the AFM tip and S. aureus could be 
adhered to an NO-releasing xerogel.  The interactions between the fibrinogen-modified tip 
and the bacterial cell adhered to an NO-releasing surface could be examined as a function of 
time and/or NO-release properties (e.g., flux of NO, total NO concentration, and xerogel 
composition).  If the interaction between fibrinogen and the fibrinogen receptors is 
unaffected by NO exposure, then researchers can conclude NO does not reduce fibrinogen-
mediated bacterial adhesion by disrupting the specific fibrinogen-receptor interactions but 
more likely affects bacterial cell adhesion via a fibrinogen-independent mechanism.   
 
    6.2.5 AFM investigations of reactive species and fibrin(ogen)-fibrin interactions.  In 
addition to investigating the influence of NO on fibrinogen-bacteria interactions, the AFM 
could be used to investigate the influence of NO or S-nitrosothiols on fibrin(ogen)-fibrin 
interactions.  Chapter 4 demonstrated glutathione and its derivatives influence several aspects 
of fibrin formation via prolonged lag times, slower rates of lateral aggregation and lower 
final turbidities.  The effect of glutathione and its derivatives on fibrinogen has not been 
examined at the single molecule level.  Investigating alterations in fibrinogen function using 
the AFM method developed in Chapter 3 could provide unique information not measurable 
using other techniques.  It would be interesting to investigate whether NO or S-nitrosothiols 
influence both the magnitude of the rupture and the deformation pattern observed upon the 
dissociation of the “A-a” knob-hole interaction.  Understanding the consequences of NO or 
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nitrosothiol exposure to fibrinogen at the single molecule level could provide insight into 
fibrinogen’s structure and/or function that is not measurable in global turbidity assays.  For 
example, Chapter 4 found glutathione likely reduces a critical disulfide in the αC domains of 
fibrinogen, leading to impaired polymerization.  If additional disulfides are reduced, the 
turbidity curve may not be affected but further modifications may be manifested at the single 
molecule level.  AFM would be useful for assessing modifications to fibrinogen’s structure 
that may affect mechanical properties but not lead to measurable changes in turbidity.   
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